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As the average lifespan continues to rise, there is a significant increase in the number of 
people suffering from age-related chronic inflammatory diseases such as autoimmune disorders, 
cancer, and neurodegenerative diseases. Therefore, there is a greater need to understand the 
factors that contribute to quality of life in the elderly. Growing evidence indicates that the 
immune system plays a critical role in regulating the progression of brain aging. However, an 
important question remains of whether inflammatory pathways become hyperactivated with age, 
or whether deficient immune responses, which fail to cope with age-related deterioration, may 
contribute to disease.  
Microglia, the resident immune cells of the brain, are key players in regulating 
neuroinflammation. They function as the primary immune surveillance, provide the first host 
defense by secreting factors such as cytokines and chemokines, and carry out specific central 
nervous system functions such as synaptic pruning and secretion of neurotrophic factors. Of 
note, microglia are also long-lived within the brain and have a limited turnover, suggesting that 
they are a likely target for epigenetic regulation.  
 In order to determine possible causes and targets for interventions to promote healthy 
aging, the current dissertation explored the role of epigenetic regulation in microglia as well as 
potential pharmacological and dietary interventions that could be beneficial for chronic age-
related neuroinflammation. This dissertation was divided into three major sections. In Chapter 2, 
we determined that aged mice had decreased methylation of the Il1b gene promoter in primary 
microglia basally or following systemic lipopolysaccharide (LPS) that is associated with 
increased Il1b mRNA, intracellular IL-1β production, as well as prolonged sickness behavior. 
We also determined changes in epigenetic regulator gene expression with both age and LPS. 
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Furthermore, we found that inhibiting DNA methylation increased Il1b gene expression and 
decreased DNA methylation of BV2 and primary microglial cells similar to microglia from aged 
mice. In Chapter 3, we investigated whether inhibiting DNA methylation in the brain of adult 
mice would alter sickness behavior, DNA methylation of the Il1b promoter and expression of 
inflammatory genes in microglia similar to aged mice. However, we found that inhibiting DNA 
methylation and injecting LPS in the brain of adult mice produced faster recovery of burrowing 
behavior compared to mice treated only with LPS. Genes of inflammatory markers, epigenetic 
regulators, and the microglial sensory apparatus (i.e. the sensome) were also differentially 
expressed by inhibiting DNA methylation alone or in combination with LPS. Lastly, DNA 
methylation of Il1b proximal promoter was changed by inhibiting DNA methylation alone or in 
combination with LPS, and these changes persisted 48 hours after LPS treatment. In Chapter 4, 
we investigated whether injections of butyrate or increases in butyrate through a highly 
fermentable diet could affect microglial activation, and specifically microglial activation in 
aging. We determined that gene expression of inflammatory markers, epigenetic regulators, and 
the microglial sensome were altered by both diet and age, in that aged animals had a more anti-
inflammatory profile on the high fiber diet.  
In summary, the studies outlined in this dissertation comprise evidence that epigenetic 
changes are present in aging microglia, and that pharmacological agents and nutrients that act as 
epigenetic modifiers can alter microglial phenotypes. This could lead to the development of 
therapeutic interventions aimed at specifically promoting beneficial microglia reactivity 
associated with infection, which may be important for fostering better recovery from sickness 
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CHAPTER 1: INTRODUCTION 
1.1 Aging and Neuroinflammation 
Most research focuses on the diseases of aging, yet the healthy aging brain undergoes a 
number of changes in the absence of disease. Structural and functional changes include decreases 
in brain mass, altered hippocampal and neocortical circuits, and increased permeability of the 
blood-brain barrier (BBB) (Montagne et al., 2015; Morrison & Hof, 2002; Peters, 2006). 
Moreover, cellular changes include telomere shortening, improper maintenance of metabolic 
homeostasis, increases in oxidative stress and DNA damage, as well as an increase in 
inflammatory activity (Chung et al., 2009; Ivanisevic et al., 2016; Pal & Tyler, 2016; Sparkman 
& Johnson, 2008). This can confer risk to age-associated pathologies such as cancer, 
autoimmunity, and neurodegenerative diseases. 
Generally, neuroinflammation is beneficial as an acute, transient response to injurious 
conditions such as tissue damage or infection, the primary goal being to remove harmful agents 
and facilitate recovery through activation of receptors and production of cytokines and proteins. 
However, mechanisms responsible for limiting inflammation become altered during aging, 
leading to low-grade and persistent neuroinflammation, even in the absence of a pathologic 
stimulus (Pizza, Agresta, D'Acunto, Festa, & Capasso, 2011; von Bernhardi, Eugenín-von 
Bernhardi, & Eugenín, 2015). 
It was once thought that the brain was an “immune-privileged” organ due to its seclusion 
by the BBB, but there are now many recognized routes of communication between the immune 
system and brain (Quan & Banks, 2007). The signals required to convey the information between 
these two systems are inflammatory mediators that predominantly consist of cytokines. The 
major pathways of communication include passive diffusion of cytokines from the blood to the 
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brain via regions of the brain that lack a BBB (circumventricular organs), passage of cytokines 
through energy-dependent, saturable transport systems on brain endothelium, activation of 
cytokine receptors on endothelial cells that form the BBB that subsequently release cytokines or 
second messengers, and transmission of cytokine signals via afferent nerve fibers, such as the 
vagus nerve. Further, with the recent discovery of functional lymphatic vessels lining the dural 
sinuses, there is an additional way in which brain-resident immune cells communicate with 
peripheral immune cells (Aspelund et al., 2015; Louveau et al., 2015). 
Chronic neuroinflammation attributed to dysregulation of the brain-immune pathways 
mentioned above is an important factor contributing to age-related cognitive decline (Simen, 
Bordner, Martin, Moy, & Barry, 2011). Animal studies show that increased levels of 
inflammatory molecules in the brain impair behavioral and cognitive performance. Mice or rats 
injected intraperitoneally with lipopolysaccharide (LPS), a cell wall component of gram-negative 
bacteria, have increased interleukin (IL)-1β in the brain, which is associated with impairments in 
spatial working memory, contextual fear conditioning, and classic signs of sickness behavior 
including loss of appetite, sleep, and anhedonia (Dantzer, 2009; Dantzer, O'Connor, Freund, 
Johnson, & Kelley, 2008).  All of these behaviors can be recapitulated by injecting recombinant 
IL-1β directly into the brain (Dantzer, 2001).  Furthermore, injecting IL-1 receptor antagonist 
(IL-1RA) into the brain can prevent many age-associated deficits caused by immune stimuli in 
the periphery, including dysfunction of hippocampal long-term potentiation and exaggerated 
LPS-induced sickness behaviors (Abraham & Johnson, 2009; Chapman, Barrientos, Ahrendsen, 
Maier, & Patterson, 2010).  
In human studies, increases in the cytokines IL-6 and tumor necrosis factor (TNF)-α as 
well as the acute-phase protein C-reactive protein have been found in serum in elderly men and 
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women, and this increase is inversely related to performance on attention/working memory and 
executive function tasks (Simen et al., 2011). Furthermore, aged individuals are increasingly 
sensitive to insults such as infections, stress, or recent surgical procedures, and often experience 
cognitive and behavioral consequences that are more intense and prolonged than in adults. It is 
still unclear whether peripherally or centrally derived cytokines play a larger role in eliciting 
central responses, but regardless, the immune cells of the brain, microglia, and the cytokines they 
produce, are key components of both the central and overall immune response. Mounting 
evidence suggests that age-related dysregulation of microglial cell activity may be responsible 
for a discordant central response to peripheral immune signals (Dilger & Johnson, 2008).  
1.2 Microglia 
Microglia account for around 10% of all cells within the brain, and show relatively 
limited turnover (L. J. Lawson, Perry, Dri, & Gordon, 1990; Mittelbronn, Dietz, Schluesener, & 
Meyermann, 2001; R. M. Ransohoff & Perry, 2009; Tay et al., 2017). They develop early in 
embryogenesis in the embryonic yolk sac and migrate to the central nervous system (CNS) 
where they remain and are rarely replaced (Ginhoux et al., 2010). Once thought of as “resting” or 
“quiescent” cells in the healthy brain, it is now known that microglia are far from inactive and 
many recent in vivo observations have shown that microglia extend their processes to actively 
scan the microenvironment (Nimmerjahn, Kirchhoff, & Helmchen, 2005; Wake, Moorhouse, 
Jinno, Kohsaka, & Nabekura, 2009). When sensing a danger associated molecular pattern (e.g., 
ATP or heat shock proteins), or a pathogen associated molecular pattern (e.g., LPS), microglia 
enlarge their cell body and become activated. Depending on the stimuli, microglia exhibit 
different activation patterns. Quiescent surveying microglia (M0) can become M1, or 
“classically” activated cells, as defined by the release of cytokines and chemokines that promote 
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inflammation, including IL-1β, TNF-α, IL-6, and IL-18. A second type of microglia known as 
M2, or “alternatively” activated cells, produce anti-inflammatory cytokines and neurotrophic 
factors that facilitate healing such as IL-4, IL-10, IL-1RA, and brain-derived neurotrophic factor. 
(Cherry, Olschowka, & O’Banion, 2014). Activated microglia are generally categorized as M1 or 
M2, but given the complexity of their behavior, this classification may be over-simplistic and, in 
actuality, microglia may show a continuous spectrum of activation patterns depending on the 
nature of stimulation (Richard M. Ransohoff, 2016). An increasing number of transcriptomic 
studies using primary microglia have revealed gene signatures extending far beyond “M1” and 
“M2” genes (Orre et al., 2014; Wes, Holtman, Boddeke, Möller, & Eggen, 2016). Notably, 
Hickman et al. identified 100 genes specifically enriched in microglia that were collectively 
named the microglial sensome, thus creating a new way to discriminate between other CNS cells 
and immune cells (Hickman et al., 2013). 
Despite the dynamic role of microglia in maintaining homeostasis, their long-lived nature 
and general inability to be replaced by circulating peripheral cells makes them particularly 
sensitive to oxidative stress, DNA damage, and a lifetime of inflammatory insults. Aged 
microglia display a deramified morphology, with fewer and shorter processes and increased 
soma volume. They lose their homogeneous tissue distribution, and are less efficient at clearing 
damaged neurons due to ineffective phagocytosis (Damani et al., 2011).  
Over time, these cells may also become hypersensitive or primed. With normal aging, 
microglia are characterized by up-regulation of glial activation markers including major 
histocompatibility complex II (MHC II), cluster of differentiation molecule 11b (CD11b), and 
CD68, a finding that is consistent in several species including human post-mortem tissue, 
rodents, and non-human primates (Conde & Streit, 2006; Perry, Matyszak, & Fearn, 1993; 
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Sheffield & Berman, 1998; Sobel & Ames, 1988). For example, approximately 25% of microglia 
isolated from aged mice stain positive for major histocompatibility complex class II compared to 
less than 3% of microglia isolated from young adults (Henry, Huang, Wynne, & Godbout, 2009). 
Microglia from aged brains also show increased basal production of the pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α and decreased production of the anti-inflammatory cytokines 
IL-10 and IL-4. Accordingly, when the immune system is challenged by a pro-inflammatory 
agent such as LPS, microglial activation is amplified and prolonged in the aged brain compared 
with adults, leading to exaggerated neuroinflammation, sickness behavior and cognitive deficits 
(Godbout et al., 2005; Henry et al., 2009). It has even been recently found that exaggerated 
microglial responses to systemic inflammation are evident as early as middle age (9-10 month-
old mice), which may have more profound consequences for age-related diseases than previously 
thought (M. Nikodemova, Small, Kimyon, & Watters, 2016). In order to validate the link 
between microglial phenotypes and age-related neuroinflammation, pharmacological and dietary 
manipulations that control microglial activation states have been explored, but very little has 
been documented on their epigenetic regulation. It has recently been proposed that microglial 
priming should be viewed as a type of trained immunity in the brain, which refers to the ability 
of mainly peripheral cells to display a ‘memory’ to inflammation through epigenetic 
reprogramming (Haley, Brough, Quintin, & Allan, 2017; Netea et al., 2016). As the immune 
system needs to respond to rapidly changing environmental cues to ensure an appropriate host 
response to pathogens, the molecular regulation of inflammatory responses is a likely target for 






Epigenetics refers to changes in gene expression that are not dependent on DNA 
sequence, and is thought of as a mediator between gene-environment interactions (Bird, 2002). 
The concept of DNA as a static, fixed entity has been replaced by a new vision where DNA is 
highly dynamic, capable of large fluctuations, and able to interact actively with the environment 
(M. Szyf, McGowan, & Meaney, 2008). Epigenetic mechanisms are mediated by post-
translational modifications of histones such as acetylation and methylation, non-coding RNA, 
and by methylation and more recently hydroxymethylation of DNA.  
DNA methylation is the most well-studied epigenetic mechanism. When DNA is 
methylated, methyl groups from S-adenosyl-L-methionine are covalently transferred to cytosines 
in cytosine-guanine (CpG) dinucleotides (Jin, Li, & Robertson, 2011). These sequences can be 
found primarily within the promoter region of a gene and thus are in a good place to control the 
level of expression of a gene. DNA methylation is catalyzed by a family of DNA 
methyltransferases (DNMTs) that includes DNMT1, DNMT3a, and DNMT3b (Moore, Le, & 
Fan, 2013). DNMT1 is a maintenance methyltransferase that adds methyl groups to the 
complimentary strand of hemimethylated DNA, and maintains DNA methylation patterns during 
the DNA replication process. DNMT3a and DNMT3b are de novo methyltransferases, capable of 
catalyzing new methylation patterns of previously unmethylated sequences. Of note, the DNMT 
family also includes DNMT2, which acts as an RNA methyltransferase (Jurkowski et al., 2008), 
and DNMT3L, which exhibits no enzymatic activity, but plays a role in DNMT3a activity (Ooi 
et al., 2007). Methylated DNA can recruit methyl-CpG-binding domain (MBD) proteins such as 
Methyl-CpG Binding Protein-2 (MeCP2) and other corepressors like histone deacetylases 
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(HDACs), which recognize 5-methylcytosines (5-mC) and participate in chromatin silencing 
(McCabe, Brandes, & Vertino, 2009) 
DNA demethylation can also occur, and is thought to be initiated by the oxidation of 5-
mC into 5-hydroxymethylcytosine (5-hmC) by the ten-eleven translocation (TET) proteins 
(Kohli & Zhang, 2013). Additionally, Growth Arrest and DNA-Damage-Inducible (Gadd45) 
proteins assist in the localization of demethylation activity to specific gene promoters. It would 
be challenging to break the strong covalent bonds between methyl groups and cytosines, so 
instead Gadd45 functions through a DNA-repair-like mechanism, in which an unmethylated 
cytosine replaces the methylated cytosine following a sequence of molecular events (Ma, Guo, 
Ming, & Song, 2009).  
Histone acetylation and methylation are the most studied modifications of histone 
proteins. The state of histone acetylation depends on histone acetyltransferases (HATs) and 
HDACs, enzymes responsible for acetylation and deacetylation, respectively (Bannister & 
Kouzarides, 2011). HATs, that transfer an acetyl group from acetyl-CoA on lysine histone tails, 
cause a loosening of the the chromatin structure by weakening electrostatic attraction between 
the histone proteins and DNA. This typically allows transcription factors to bind and increase 
transcription of a particular gene. HDACs act to remove acetyl groups from lysine histone tails, 
promoting chromatin condensation and not allowing transcription factors to bind, thus decreasing 
gene expression. In contrast, histone methylation may be linked to gene activation or repression, 
depending on the position where methylation is occurring, which is either at lysine or arginine 
residues of histones H3 or H4 (Kouzarides, 2007). Methylation is controlled by histone lysine 
methyltransferases (HKMTs) and protein arginine methyltransferase (PRMT), respectively, 
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whereas demethylation is controlled by histone lysine demethylases (HKDMs) and histone 
arginine demethylases (HRDMs).  
It is well-documented that epigenetic changes contribute to aging and alter the lifespan 
(Hernandez et al., 2011; Zampieri et al., 2015). DNA methylation depends on a precise balance 
of methylation and demethylation reactions that are nicely balanced in mature cells, but with age 
this balance is strongly shifted to favor DNA hypomethylation (Pogribny & Vanyushin, 2010a). 
This could be due to passive age-dependent decline in DNA methylation, the increase of active 
DNA demethylation, or both. This could be linked to decreased methylation capacity of DNA 
methyltransferases caused by compromised genome integrity and/or the age-dependent decrease 
in the activity of DNA methyltransferases (Bollati et al., 2009; Lopatina et al., 2002). Histone 
modifications also undergo age-related alterations, including global loss of core histone proteins, 
and decreases in acetylation of histone 3 lysine 9 (H3K9Ac) and trimethylation of histone 3 
lysine 27 (H3K27me3) (Bracken et al., 2007; Kawakami, Nakamura, Ishigami, Goto, & 
Takahashi, 2009). Not surprisingly, DNA methylation and histone modifications are dependent 
on one another to exert the changes observed during aging (Pal & Tyler, 2016). Therefore, it 
seems that age-associated alterations in epigenetic mechanisms like DNA methylation and 
histone modifications may lead to redistribution of heterochromatin, impair normal gene 
responsiveness to environmental signals, and increase genomic instability that could compromise 
cell function and contribute to a generalized functional decline. Aging could therefore be thought 
as a time-dependent, epigenetically mediated loss of phenotypic plasticity (Gravina & Vijg, 
2010).  
The cellular and physiological phenotype of aged microglial cells is likely related to 
epigenetic changes such as DNA methylation and histone modifications. To date, only a handful 
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of studies have used high-throughput sequencing to address the epigenetic landscape of primary 
microglia (Gosselin et al., 2014; Lavin et al., 2014), and there is yet to be a study comparing 
young to old. Fortunately, a number of recent studies have investigated specific epigenetic 
regulators in microglia. Sirtuin 1 (SIRT1) is a member of class III histone deacetylases and is 
known to play a role in longevity (Satoh et al., 2013). SIRT1 deficiency in aged microglia is 
related to increases of IL-1β transcription and decreased methylation of CpG sites within the IL-
1β proximal promoter (Cho et al., 2015). As epigenetic regulation of other pro-inflammatory 
genes such as TNF- α and IL-6 has been demonstrated in other immune cell types (Eddy, 
Krukowski, Janusek, & Mathews, 2014; Sullivan et al., 2007), it will be pertinent to explore this 
possibility in microglia. It has also been observed that the suppressing histone H3K27me3 
demethylase Jumonji domain containing 3 (Jmjd3) in the substantia nigra in vivo caused 
exaggerated microglial activation and provoked greater dopamine neuron death in a mouse 
model of Parkinson’s disease (Tang et al., 2014). Moreover, the Jmjd3 level was lower in the 
midbrain of aged mice, which was accompanied by an elevated level of H3K27me3.  
Since epigenetic modifications are controlled by reversible enzymatic reactions, they 
have the potential to be modulated by pharmacological agents (Moshe Szyf, 2017). Utilizing 
compounds that act as DNMT inhibitors (DNMTis) or HDAC inhibitors (HDACis) could 
reprogram pathological states and may identify new therapeutic targets for disease. Both 
DNMTis and HDACis have primarily been studied for cancer therapy, acting as tumor 
suppressors that increase the expression of tumor suppressor genes (Kristensen, Nielsen, & 
Hansen, 2009; Song, Han, & Bang, 2011), but they have also been recently shown as promising 
treatments for autoimmune, neurodegenerative, and psychiatric disorders (Heerboth et al., 2014; 
M. Szyf, 2009). Further, a handful of studies have demonstrated the effect of gene expression 
10 
 
regulation by DNMTis and HDACis in microglial behavior. For example, the DNMTi 5-aza-2'-
deoxycytidine influences expression of several genes associated with the pathology of 
Alzheimer’s disease in microglia-like BV-2 cells, (Byun et al., 2012). Butyrate, a short chain 
fatty acid that will be discussed in more detail in a later section (1.5), has also been shown to be 
anti-inflammatory in LPS treated microglial cell cultures and in microglia in rodent models of 
ischemic stroke (Durham, Grigg, & Wood, 2017; Huuskonen, Suuronen, Nuutinen, Kyrylenko, 
& Salminen, 2004; Patnala, Arumugam, Gupta, & Dheen, 2016). This leads to the hypothesis 
that these drugs have the ability to regulate age-related microglial activity. 
1.4 Gut-Brain-Axis  
The gastrointestinal (GI) tract is the most heavily colonized region of the human body, 
with bacterial concentrations ranging from 101–103 cells per gram in the upper intestine to 1011–
1012 per gram in the colon (Derrien & van Hylckama Vlieg, 2015; O'Hara & Shanahan, 2006). A 
recent sequencing study has also revealed that the microbiota in our gut comprise approximately 
40,000 bacterial species (Frank & Pace, 2008). The intestinal barrier regulates the absorption of 
nutrients from the lumen into the circulation, but also acts as part of the host defense against 
microorganisms (Peterson & Artis, 2014). A mucus layer, composed of highly glycosylated 
proteins called mucins that are produced and maintained by goblet cells (Johansson, Larsson, & 
Hansson, 2011), contains secretory immunoglobulin (Ig) A and antimicrobial peptides that cover 
the epithelial cell lining. This functions to facilitate GI transport, and works as a protective layer 
against bacterial invasion. Additionally, to establish a barrier to paracellular transport, there is a 
monolayer of epithelial cells interconnected by tight junction proteins, including claudin, 
occludin, and tricullulin (Dorfel & Huber, 2012; Ivanov, Parkos, & Nusrat, 2010).  
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It is becoming increasingly clear that through bi-directional communication with the 
brain, the bacterial commensals help to maintain homeostasis of the CNS and influence 
neurotransmission and behavior. This is known as the microbiota–gut–brain axis. In the brain, 
endothelial cells separate the lumen of blood vessels from the CNS parenchyma, and are 
connected by the same tight junction proteins as intestinal epithelial cells (Doran, Banerjee, 
Disson, & Lecuit, 2013). Not surprisingly, there is evidence that the microbiota from the gut can 
modulate the BBB. Germ free mice have increased BBB permeability and decreased expression 
of tight junction proteins, and exposure of GF adult mice to the fecal microbiota from pathogen-
free donors restores BBB permeability and tight junction protein expression (Braniste et al., 
2014). The microbiota can signal to the brain through a variety of other mechanisms as well, 
including production of bacterial metabolites and immune mediators, such as cytokines, and 
signaling to the brain directly via the vagus nerve (Sherwin, Sandhu, Dinan, & Cryan, 2016).  
Importantly for our research, the immune system acts as a key intermediary between the 
gut microbiota and the brain (El Aidy, Dinan, & Cryan, 2014). For instance, intestinal 
inflammation in mice was associated with increased neuronal activation, represented by c-Fos 
immunohistochemistry, in vagal sensory ganglia and in the nucleus of the solitary tract, which is 
the primary afferent of the vagus nerve (Goehler et al., 2005). In addition, the anxiety-like 
behavior in a mouse model of chronic colitis was attenuated following vagotomy, indicating that 
the vagus nerve is an intermediary in facilitating the detrimental behavioral effects of colonic 
inflammation (Bercik et al., 2011).  
Recently, research has revealed that the microbiota can specifically regulate microglia 
function (Erny et al., 2015).  Germ free mice were found to have an increased number of ionized 
calcium-binding adapter molecule 1 (Iba1) positive microglia in the cortex and hippocampus, 
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and these microglia displayed an immature phenotype, lacking the markers CD44, CD62L and 
MHC class II. They also failed to display an activated phenotype following LPS administration. 
Antibiotic treatment, which depletes microbiota, produces this same effect upon microglial 
morphology and activation as well (Erny et al., 2015). Further, new evidence suggests that the 
maternal microbiome can influence microglial properties during prenatal stages and that the 
depletion of the microbiome can impact microglia in a sex- and time-specific manner 
(Matcovitch-Natan et al., 2016; Thion et al., 2018). 
Just as in the aging brain, there are changes with permeability and immune function as 
the gastrointestinal tract ages (Biagi et al., 2013). The impairment of the gut associated lymphoid 
tissue to efficiently synthesize secretory IgA, together with the reduced efficiency of the innate 
immune defenses, such as antimicrobial peptides and mucus secretion, can result in failure to 
control microbiota, possibly creating an excessive bacterial load. The fact that microbiota are key 
regulators of immune function and inflammatory responses, it is likely that a change in their 
composition as well as intestinal permeability during aging plays a role in the gradual activation 
of the immune system, which could then lead to inflammation of the brain (Guigoz, Dore, & 
Schiffrin, 2008; Kelly et al., 2015).  
1.5 Fiber and Butyrate 
A large body of literature has demonstrated the benefits of a high fermentable fiber diet 
in the colon, including reducing risk of type 2 diabetes, colon cancer, obesity, and cardiovascular 
disease (Slavin, 2013). Bacterial fermentation of fiber in the colon produces a class of molecules 
known as short-chain fatty acids (SCFAs), with acetic, propionic and butyric acids being the 
most studied. These metabolites are found in high concentrations in the intestinal tract, and are 
taken up by colonocytes as their predominant ATP source. In addition, SCFAs modulate 
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colonocyte and immune cell development and survival, as well as intestinal barrier function, 
through activation of G protein coupled receptors (FFAR2, FFAR3, GPR109a) and by histone 
modifications, predominantly HDAC inhibition (Corrêa-Oliveira, Fachi, Vieira, Sato, & Vinolo, 
2016).  
Many of the reported beneficial effects of fiber have been associated with the 
microbiome and its ability to produce the SCFA butyrate. Studies have demonstrated that 
butyrate is anti-inflammatory, modulating development, function, and activation of peripheral 
immune cells such as neutrophils, macrophages, and dendritic cells (Corrêa-Oliveira et al., 
2016). Butyrate also exerts a protective role in the intestinal epithelium, stimulating the release 
of mucins, improving tight junction integrity, thus improving gastrointestinal homeostasis by 
reducing intestinal permeability (Bischoff et al., 2014). As there is a lower capacity to produce 
butyrate in the elderly gut microbiome, due to the findings of significantly fewer copies of the 
butyrilCoA:acetateCoA transferase gene compared to younger adults and lower amounts of 
bacterial groups which are known butyrate producers (Biagi, Candela, Franceschi, & Brigidi, 
2011; Hippe et al., 2011), an increase in butyrate through a high fiber diet could counterbalance 
the age-related microbiota depletion. Of note, inulin has been shown to be a rich source of 
soluble dietary fiber that increases butyrate-producing bacteria (G. Schaafsma & Slavin, 2015).  
Inulin belongs to a group of non-digestible carbohydrates called fructans, and in food is 
considered a prebiotic (Roberfroid, 2007). Inulin has even been shown to be beneficial for age-
related inflammation, as a nutritional supplement with inulin increased innate immunity and 
protection against infections in elderly people (Bunout et al., 2004). 
Pharmacologically, there is substantial evidence that butyrate has a profoundly beneficial 
effect on brain disorders (Sherwin et al., 2016). Specifically, the HDACi properties of butyrate 
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have attractive therapeutic potential due to its ability to increase histone acetylation and promote 
the expression of neurotrophic genes. For example, sodium butyrate (NaB), the sodium salt of 
butyrate, can protect neurons from cell death in models of Parkinson’s disease (Sharma & 
Taliyan, 2015). NaB also demonstrated a profound effect on improving learning and memory, as 
treatment in a mouse model of Alzheimer’s disease restored histone acetylation, expression of 
learning-associated genes, and improvement in contextual memory (Govindarajan, Agis-Balboa, 
Walter, Sananbenesi, & Fischer, 2011; Kilgore et al., 2010). As mentioned previously, butyrate 
is also capable of regulating microglia (Huuskonen et al., 2004; Patnala et al., 2016). Moreover, 
long-term SCFA treatment has been reported to reverse microglial immaturity and malformation 
observed in germ-free mice, which was dependent upon activation of FFAR2 (Erny et al., 2015).  
Evidence indicates that high fiber, butyrate-producing diets are capable of improving the 
health of our brains, although this is largely understudied (Bourassa, Alim, Bultman, & Ratan, 
2016).  One study found significant immune benefits in the brain of mice fed a high fermentable 
(soluble) fiber diet and found that they recovered faster from LPS-induced sickness (Sherry et 
al., 2010). After exposure to LPS, mice fed the soluble fiber diet showed an increase in IL-1RA 
and a decrease in IL-1β and TNF-α in the brain. Brain IL-4 mRNA was also increased, and as 
IL-4 expression is enhanced by increased histone acetylation, the authors hypothesized that the 
elevated butyrate from the dietary fiber fermentation may contribute to the immune response. It 
is still not fully understood however, if an increase in butyrate-producing bacteria in the gut as a 
consequence of soluble fiber diet, could affect microglial activation, and specifically microglial 






As age-related microglial dysfunction could lead to pathologies such as autoimmune and 
neurodegenerative diseases, there is an urgent need to define the underlying mechanisms 
responsible for the contribution of microglia in chronic neuroinflammation. Although there is an 
increasing amount of data indicating that epigenetics play a role in aging, aging-related diseases, 
microglial phenotype, and pro-inflammatory cytokine regulation, to my knowledge these 
research areas have never been synthesized and looked at collectively. Thus, my dissertation 
research is focused on discovering relationships between epigenetic modifications and microglial 
activation, as well as using pharmacological agents and nutrients that act as epigenetic modifiers 
to alter microglial phenotypes. Understanding and manipulating the epigenome holds promise for 
preventing and treating age-related diseases, such as therapies targeted to restore the DNA 
methylation and histone modification profile of aging cells to that of young cells. Specifically, a 
better understanding of how epigenetic mechanisms become dysregulated with age in microglia 
is needed to improve our understanding of what triggers neuroinflammatory complications 











CHAPTER 2: AGING AND PERIPHERAL LIPOPOLYSACCHARIDE CAN 
MODULATE EPIGENETIC REGULATORS AND DECREASE IL-1β PROMOTER 
DNA METHYLATION IN MICROGLIA 
Adapted from Neurobiology of Aging (renumbered figures and formatting). Matt, S. M., Lawson, 
M. A., & Johnson, R. W. (2016). Aging and peripheral lipopolysaccharide can modulate epigenetic 
regulators and decrease IL-1β promoter DNA methylation in microglia. Neurobiol Aging, 47, 1-9. 
doi:10.1016/j.neurobiolaging.2016.07.006, with permission from Elsevier. 
 
2.1 Abstract  
In aged mice, peripheral stimulation of the innate immune system with 
lipopolysaccharide (LPS) causes exaggerated neuroinflammation and prolonged sickness 
behavior due in part to microglial dysfunction. Epigenetic changes to DNA may play a role in 
microglial dysfunction; therefore, we sought to determine whether aged microglia displayed 
DNA hypomethylation of the interleukin-1 beta (IL-1β) promoter and altered expression of 
epigenetic regulators. We further examined whether the demethylating agent 5-azacytidine 
induced IL-1β expression in BV2 and primary microglia similar to microglia from aged mice. 
Novel findings indicated that aged mice had decreased methylation of the IL-1β gene promoter 
in primary microglia basally or following systemic LPS that is associated with increased IL-1β 
mRNA, intracellular IL-1β production, as well as prolonged sickness behavior. Last, 5-
azacytidine increased IL-1β gene expression and decreased DNA methylation of BV2 and 
primary microglial cells similar to microglia from aged mice. Taken together, these data indicate 
that DNA methylation promotes heightened microglial activation in the aged brain. 
2.2 Introduction 
In the aged brain, it is common for microglia to have an inflammatory gene expression 
profile and a deramified morphology com- parable to the morphology of activated adult 
microglia (Damani et al., 2011; Sierra, Gottfried-Blackmore, McEwen, & Bulloch, 2007; 
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Tremblay, Zettel, Ison, Allen, & Majewska, 2012). What’s more, microglia in the brain of aged 
animals are hypersensitive to signals emerging from the peripheral immune system during 
infection, resulting in an aberrant neuroinflammatory response that is more intense and longer 
lasting (Dilger & Johnson, 2008; Henry et al., 2009; Sierra et al., 2007). This exaggerated 
proinflammatory response can be neurotoxic, lead to behavioral pathology (e.g., anorexia, acute 
cognitive disorders, and delirium) and exacerbate neurodegenerative diseases (e.g., Alzheimer’s 
disease), greatly enhancing morbidity and mortality in older adults (Franceschi & Campisi, 
2014). Why microglia become proinflammatory during aging and why they are hypersensitive to 
signals from the peripheral immune system is not known.  
One way that microglial dysfunction may occur is through epigenetic modifications. 
Epigenetics refers to changes in gene expression that are independent of changes in the DNA 
sequence; it is thought of as a mediator between gene environment interactions (Bird, 2007; 
Jaenisch & Bird, 2003). Epigenetics impact gene regulation though mechanisms such as DNA 
methylation and posttranslational modifications to histone tails, with DNA methylation being the 
most well-studied mechanism. DNA methylation is catalyzed by DNA methyltransferases 
(DNMTs) that includes DNMT1, DNMT3a, and DNMT3b (Moore et al., 2013). DNMT1 is a 
maintenance methyltransferase that maintains DNA methylation patterns during the DNA 
replication process, whereas DNMT3a and DNMT3b are de novo methyltransferases, capable of 
catalyzing new methylation patterns of previously unmethylated sequences. Another protein 
associated with DNA methylation is MeCP2, which binds to methylated cytosines and recruits 
histone deacetylases (HDACs) and other corepressors. This promotes higher-affinity interaction 
between DNA and histone core, condensing the chromatin, and typically suppresses transcription 
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factor binding and gene expression (Bird, 2002; Strahl & Allis, 2000). In addition, Gadd45b 
protein plays an important role in active DNA demethylation (Ma et al., 2009).  
DNA methylation depends on a precise balance of methylation and demethylation 
reactions that are nicely balanced in mature cells, but with age, there is a strong shift to favor 
DNA hypomethylation (Pogribny & Vanyushin, 2010b). Age-related DNA hypomethylation 
may lead to redistribution of heterochromatin, impair normal gene responsiveness to 
environmental signals, and increase genomic instability that could compromise proper cell 
function. Aging could therefore be thought of as a time- dependent, epigenetically mediated loss 
of phenotypic plasticity (Gravina & Vijg, 2010), suggesting that aberrant DNA methylation 
patterns may be candidate mechanisms for explaining how microglia from aged mice seem to be 
“stuck” in a proinflammatory phenotype.  
A handful of studies have demonstrated gene expression regulation by DNA methylation 
in microglia. One using BV2 cells, a murine microglial cell line, reported that DNA methylation 
influences the expression of several genes associated with the pathology of Alzheimer’s disease 
(Byun et al., 2012), and another revealed that promoting increased maternal care alters the 
methylation pattern of the IL-10 gene, leading to increased IL-10 expression in the nucleus 
accumbens and a reduction in morphine-induced addiction behavior (Schwarz & Bilbo, 2013). 
Very recently, it has also been determined that SIRT1 deficiency in aging microglia is related to 
increased IL-1β transcription and decreased methylation of CpG sites within the IL-1β proximal 
promoter (Cho et al., 2015).  
Although increasing evidence suggests microglial phenotype is regulated by epigenetic 
mechanisms, little is known about DNA methylation of proinflammatory cytokines of healthy 
microglia from aged animals and the contribution of enzymes that significantly impact the 
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epigenetic landscape. Because it is thought that microglia are the major producers of IL-1β in the 
brain and one of the most consistently upregulated cytokines with age (Burton, Rytych, Amin, & 
Johnson, 2016; Chen et al., 2008), the objectives of this study were to determine whether there 
are promoter IL-1β DNA methylation modifications as well as altered gene expression of 
epigenetic regulators present between brain immune cells of young and old mice exposed to an 
immune challenge. Using the demethylating drug 5-azacytidine (5-aza), we also tested whether 
and how IL-1β gene expression is regulated in BV2 and primary microglial cells. We 
hypothesized that aged mice and those stimulated with an immune challenge would have IL-1β 
promoter hypomethylation associated with increased IL-1β gene expression, decreased 
expression of epigenetic regulators that promote DNA methylation, and that BV2 and adult 
primary microglial cells would have IL-1β promoter hypomethylation similar to an “aging” 
phenotype with the treatment of 5-aza.  
2.3 Methods 
Animals 
Adult (4- to 6-month old) C57BL/6 mice were either purchased from Charles River or 
reared in-house, and aged (24- to 26-month old) C57BL/6 mice were purchased from the 
National Institute on Aging. They were individually housed in a temperature-controlled 
environment with a reversed-phase light/dark cycle (lights on 9 PM). Mice that were purchased 
were allowed to acclimate to their environment for at least 4 weeks before experimentation. All 
studies were carried out in accordance with United States National Institutes of Health guidelines 






Escherichia coli lipopolysaccharide (LPS; serotype 0127:B8, Sigma, St. Louis, MO, 
USA) was dissolved in sterile saline before experimentation. Mice from both age groups were 
given LPS (0.33 mg/kg body weight) or saline intraperitoneal. This dose of LPS was selected 
based on previous studies demonstrating that 0.33 mg/kg LPS produced prolonged sickness 
behavior in aged compared with young mice (Godbout et al., 2005). Treatments were 
administered at 9 AM for all cohorts.  
Behavioral Testing 
Sickness behavior was assessed by changes in body weight and locomotor activity. Body 
weight and locomotor behavior were measured at baseline and 4 or 24 hours after treatment. 
Mice were placed in clear plexiglass cages identical to their home cage but devoid of bedding or 
nesting material. Clear plexiglass lids were placed on top of test cages to prevent escape while 
facilitating video recording. Locomotor activity was evaluated by virtual division of the cage into 
4 equal quadrants and then tallying the number of line crossings and rearings each mouse 
displayed during the 5-minute test period. Videos were scored by a trained experimenter blinded 
to treatment.  
Microglia Isolation 
Animals were euthanized via CO2 asphyxiation 4 or 24 hours after treatment, perfused 
with sterile ice-cold saline, and brain tissue was collected and used immediately for microglia 
isolation using a procedure adapted from Nikademova & Watters (Maria Nikodemova & 
Watters, 2012). To ensure a sufficient number of cells were recovered, tissue samples from 2 
mice were pooled within a given experimental group. Brains were enzymatically digested using 
the Neural Tissue Dissociation Kit (Miltenyi Biotec, Germany) for 35 minutes at 37 C. Further 
21 
 
processing was per- formed at 4 C. Tissue debris was removed by passing the cell suspension 
through a 40-mm cell strainer. After myelin removal using 30% Percoll Plus (GE Healthcare, 
Princeton, NJ, USA), cells in phosphate-buffered saline supplemented with 0.5% bovine serum 
albumin (BSA) and 2-mM EDTA were incubated for 15 minutes with anti-fluorescein 
isothiocyanate (FITC) magnetic beads and anti- Cd11b-FITC antibody (BD Biosciences) for 
flow cytometry or anti- Cd11b magnetic beads (Miltenyi Biotec, Germany) for gene expression 
and DNA methylation arrays. CD11b+ cells were extensively washed and separated in a 
magnetic field using MS columns (Miltenyi Biotec, Germany). Cell yields for isolated microglia 
were around 1 x 106 cells per 2 brains and were not different between treatments.  
Extracellular and intracellular flow cytometric analysis  
Flow cytometric analysis of CD11b+ cell surface and intracellular markers was performed 
based on BD Cytofix/Cytoperm Plus fixation/permeabilization protocol (BD Biosciences, San 
Jose, CA, USA), as described previously, with a few modifications (Henry et al., 2009). Isolated 
cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) (Bio-Whittaker, Cambrex, 
MD, USA) with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 units/mL 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA), and brefeldin A (BD Biosciences) at 
37 C in a humidified incubator under 5% CO2 for 4 hours. After incubation cells were washed, 
resuspended in phosphate-buffered saline/0.5% BSA/0.01% sodium azide solution (flow buffer), 
and Fc receptors were blocked with anti-CD16/CD32 antibody (eBioscience, San Diego, CA, 
USA). Cells were then incubated with anti-CD45-allophycocyanin (APC), anti-MHC-II-R- 
Phycoerthrin (PE), and anti-Ly-6C-BV421 (BD Biosciences). Next, cells were fixed and 
permeabilized with BD Cytofix/CytoPerm solution, washed and resuspended in BD Perm/Wash 
buffer, and incubated with anti- IL-1β-PE (eBioscience) for 30 minutes. Cells were washed in 
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BD Perm/Wash buffer and resuspended in flow buffer. Expression of surface and intracellular 
antigens was deter- mined using a Becton-Dickinson LSR II Flow Cytometer (Red Oaks, CA, 
USA). Ten to twenty thousand events were collected, and gating was determined based on 
fluorescently labeled isotype antibodies for FITC, APC, PE, and BV421 (BD Biosciences) 
incubated for 15 minutes with compensation beads from the AbC Total Antibody Compensation 
Bead Kit (Thermo Fisher Scientific, Grand Island, NY, USA). Unstained samples were used as 
controls. Flow data were analyzed using FCS Express software (De Novo Software, Los 
Angeles, CA, USA).  
BV2 and primary microglia cell culture and drug treatments  
BV2 cells were maintained in 150-cm2 tissue culture flasks (BD Falcon) in DMEM 
supplemented with 10% FBS and 100 units/mL penicillin/streptomycin at 37 C in a humidified 
incubator under 5% CO2. When cells reached confluence, they were passed by trypsinization, 
resuspended in serum-free DMEM, and seeded in 12-well plates (BD Falcon). Cells were treated 
one day later with 10 mM of 5-aza (Sigma, St. Louis, MO, USA) for 48 hours with daily media 
replacement and stimulated with 100 ng/mL LPS 4 or 24 hours later. Primary microglia from 
young adult mice were plated on poly-L-lysine (Sigma) coated 12-well plates in DMEM 
supplemented with 10% FBS, 100 units/mL penicillin/streptomycin, and 5 ng/mL GM-CSF and 
maintained at 37 C in a humidified incubator under 5% CO2. Cells were treated 7-8 days after 
culturing with 10-mM 5- aza for 24 hours and then 100 ng/mL LPS for 4 hours. Both media and 
cells were collected, and cells were put directly in Trizol reagent (Invitrogen) for all cell culture 
experiments. The viability of BV2 and primary-cultured microglia cells were evaluated using the 
Thermo Scientific Pierce Lactate Dehyrogenase Cytotoxicity Assay Kit (Thermo Scientific, 
Rockford, IL, USA) in accordance with the manufacturer’s instructions and was <15%.  
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Gene Expression and DNA Methylation Assays 
Total RNA and DNA from microglia were isolated using the Tri Reagent protocol 
(Invitrogen). Synthesis of complementary DNA was carried out using a high-capacity RT kit 
(Applied Biosystems, Grand Island, NY, USA) according to the manufacturer’s instructions. 
Real-time quantitative reverse transcription polymerase chain reaction was performed on an ABI 
PRISM 7900HT- sequence detection system (Perkin Elmer, Forest City, CA, USA) to detect 
changes in messenger RNA (mRNA) expression of the epigenetic regulators DNMT1 (catalog 
no. Mm.PT.58.30881142), DNMT3a (Mm.PT.58.13545327), DNMT3b (Mm.PT.58.31955137), 
HDAC1 (Mm.PT.58.43356830.g), MeCP2 (Mm.PT.58.13934895.g), and Gadd45b 
(Mm.PT.58.10699383.g), the proinflammatory cytokine IL-1β (Mm00434228_m1), and 
regulators of IL-1β processing and signaling including IL-1RA (Mm00446186_m1), NLRP3 
(Mm.PT.58.6779853.gs), and Casp1 (Mm.PT.58.8975671.gs). All genes were analyzed using 
PrimeTime real-time quantitative RT-PCR Assays (Integrated DNA Technologies, Coralville, 
IA, USA) and were compared with the housekeeping control gene GAPDH (Mm99999915_g1) 
using the 2 DDCt calculation method as previously described (Livak & Schmittgen, 2001). Data 
are expressed as fold change versus controls. To minimize unequal variances, gene expression 
for BV2 and primary cultured cells were log10 transformed for statistical analyses only. 
Methylation status was assessed via methylation-specific real-time PCR (MSP) on bisulfite-
modified DNA (Zymo Research, Irvine, CA, USA). MSP primers were designed using 
Methprimer software (http://www. urogene.org/methprimer/): (Li & Dahiya, 2002). Primer sets 
targeted a methylated and unmethylated CG dinucleotide in DNA associated with the promoter 
region of IL-1β or unmethylated b-tubulin-4 as a reference gene as previously published (Gupta 
et al., 2010; Levenson et al., 2006) and are listed in Table 2.1. Product specificity was 
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determined by melt curve analysis and gel electrophoresis. For the MSP data, a methylation 
index was calculated by dividing the fold change value for the methylated primer set by the fold 
change value for the unmethylated primer as previously described (Blaze, Scheuing, & Roth, 
2013; Sui, Wang, Ju, & Chen, 2012).  
Target Gene   Primer Sequence (5'-3')   
 
IL-1β Methylated  TTTTAGTTTAAGTATAAGGAGGCGA  
   ACACATTCGCAAATATATCATCGTA  
       
IL-1β Unmethylated  TTTTAGTTTAAGTATAAGGAGGTGA  
   AACACATTCACAAATATATCATCATA  
       
β –tubulin-4 Unmethylated GGAGAGTAATATGAATGATTTGGTG  
   CATCTCCAACTTTCCCTAACCTACTTAA 
       
Table 2.1. Primers used in methylation-specific real-time polymerase chain reaction experiments  
Global DNA Methylation Analysis 
Global DNA methylation status in primary microglia was per- formed using the 
MethylFlash Methylated DNA Quantification Kit, an enzyme-linked immunosorbent assay used 
to detect the total amount of 5 mC. The assay was run according to the manufacturer’s 
instructions (Epigentek, Farmingdale, NY, USA).  
Statistical Analyses 
All data were analyzed using Statistical Analysis System (SAS, Cary, NC, USA). 
Behavior data and data from primary microglia (not cultured) were subjected to 2-way analysis 
of variance for main effects of age and LPS and all 2-way interactions. Data from cell culture 
experiments were subjected to unpaired t-tests or 2-way analysis of variance for main effects of 
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5-aza and/or LPS, and all interactions. Where analysis of variance revealed a significant 
interaction (p < 0.10 unless noted elsewhere), Fisher’s LSD test was used for post hoc 
comparisons when appropriate. All data are expressed as means ± standard error of the mean.  
2.4 Results 
LPS-induced sickness behavior in adult and aged mice  
As previously reported in BALB/c mice (Godbout et al., 2005), aged C57BL/6 mice as 
well as those given LPS had a decrease in locomotor activity (Figure 2.1). At 4 hours, both age 
(F [1,35] = 11.83, p = 0.001) and LPS (F[1,35] = 19.51, p < 0.0001) produced a significant 
reduction in the number of line crossings during the locomotor task. At 24 hours, there was still a 
reduction in locomotor activity with age (F[1,34] = 6.24, p = 0.018) and LPS (F [1,34] = 3.68, p 








Figure 2.1. Sickness behavior in adult and aged mice after LPS. Mice were injected i.p. with sterile saline 
or LPS. Locomotor activity was measured at 4 and 24 hours post-injection. Activity of adult saline-treated 
mice at 4 hours was used for the baseline behavior. Bars represent the mean ± SEM (n = 9-10).  
 
Primary microglia had increased MHCII expression with age and increased IL-1β 
expression with age and LPS  
Adult and aged mice were injected with saline or LPS, and brain cells were isolated using 
Cd11b+ magnetic bead separation. These cells identified as CD11b+, CD45low, and Ly6C-, 
thought to be pre- dominantly microglia, were stained for IL-1β and major histocompatibility 
complex class II (MHCII) and analyzed by flow cytometry. Figure 2.2A and 2.2B show 
representative histograms and Figure 2.2C and 2.2D show the percentages of cells that were IL-
1β and MHCII+. A greater proportion of microglia from aged mice expressed MHCII compared 
with adults (F[1,12] = 43.19, p < 0.0001), whereas there was no difference between saline and 
LPS-treated mice, consistent with previous findings (Henry et al., 2009). Further, both aged 
animals and those treated with peripheral LPS had an increased percentage of IL-1β microglia 
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(F[1,12] = 16.82, p = 0.002 and F[1,12] = 5.66, p = 0.035), and there was an interaction in that 
the LPS- induced increase in IL-1β cells was greater in aged mice compared with adults (F[1, 12] 
= 3.42, p = 0.089).  
 
Figure 2.2. Differential expression of MHCII and IL-1β on microglial cells from saline (SAL) or LPS-
treated adult and aged mice. Representative histograms of Cd11b+/CD45low/Ly6C- cells incubated with 
(A) anti-MHCII PE and (B) anti- IL-1β PE compared with isotype controls. Average percentage of 
Cd11b+/CD45low/Ly6C- cells that were (C) MHCII+ or (D) IL-1β. Bars represent the mean ± standard 
error of the mean (n = 7-10). Treatment means with different letters are significantly different. 
Abbreviations: IL-1β, interleukin-1 beta; LPS, lipopolysaccharide; MHCII, major histocompatibility 
complex class II; PE, phycoerthrin.  
IL-1β promoter DNA methylation decreased in aged and LPS- treated primary microglia  
As expected, for IL-1β mRNA, there was a main effect of age (F[1, 26] = 16.39, p = 
0.0004) and LPS (F[1, 26] = 7.51, p = 0.01) at 4 hours and main effect of age (F[1, 30] = 20.18, 
p < 0.0001) and LPS (F[1, 30] = 9.9, p = 0.004) at 24 hours in that aged mice, and mice given 
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LPS had increased IL-1β compared with adult and saline-treated mice (Figure 2.3A). For IL-1β 
promoter DNA methylation, there was a main effect of age (F[1, 3] = 6.91, p = 0.02) at 4 hours 
and a main effect of LPS (F[1, 17] = 6.59, p = 0.02) at 24 hours in that aged mice, and mice 
given LPS had decreased methylation compared with adult and saline-treated mice (Figure 
2.3B). This coincides with the increase in IL-1β mRNA in aged and LPS-treated mice. DNA 
from these samples was also used to assess global methylation status, but neither age nor LPS 
significantly altered 5 mC content (data not shown).  
 
 
Figure 2.3. Increased microglial IL-1β gene expression in aged and LPS-treated mice coincides with 
decreased IL-1β promoter DNA methylation. Adult and aged mice were injected i.p. with LPS or sterile 
saline (SAL) and 4 or 24 hours later, brain tissue was collected for Cd11b+ cell isolation. Bars represent 
the mean ± standard error of the mean (n = 7-10). (A) IL-1β gene expression at 4 hours and 24 hours, and 
(B) IL-1β DNA methylation at 4 hours and 24 hours. Abbreviations: IL-1β, interleukin-1 beta; LPS, 
lipopolysaccharide.  
Epigenetic regulators are altered by age and LPS in primary microglia  
To gain a broader view of the role of epigenetic regulators in neuroinflammation, mRNA 
for several enzymes that participate in DNA methylation was measured in microglia from adult 
and aged mice 4 or 24 hours after intraperitoneal injection of LPS (Figure 2.4). Of note, there 
were decreases in DNMT3a, DNMT3b, HDAC1, and MeCP2 mRNA with age and/or LPS at 4 
and/or 24 hours. Both DNMT3a and MeCP2 had significant age LPS interactions at 24 hours in 
that aged saline-treated mice had much lower mRNA levels of DNMT3a and MeCP2 compared 
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to saline-treated adults. For Gadd45b, there were increases in mRNA with age at both 4 and 24 
hours and with LPS at 4 hours.  
 
Figure 2.4. Microglial cell gene expression of epigenetic regulators 4 and 24 hours after saline (SAL) or 
LPS. Adult and aged mice were injected i.p. with LPS or sterile saline, and 4 or 24 hours later, brain 
tissue was collected for Cd11b+ cell isolation. Data are presented as means ± standard error of the mean (n 
7-10) for (A) DNMT1, (B) DNMT3a, (C) DNMT3b, (D) HDAC1, (E) MeCP2, and (F) Gadd45b gene 
expression. Treatment means with different letters are significantly different. Abbreviations: DNMT, 
DNA methyltransferase; HDAC, histone deacetylase; LPS, lipopolysaccharide; MeCP2, methyl-CpG 
binding protein-2.  
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Inhibiting DNA methylation increased IL-1β gene expression in BV2 cells and primary 
microglia  
To demonstrate whether or not DNA methylation plays a direct role in primed microglial 
IL-1β mRNA expression, the BV2 immortalized murine microglial cell line was treated with 5-
aza for 48 hours and/or LPS for 4 or 24 hours. IL-1β promoter DNA methylation was decreased 
by 5-aza treatment (F[1, 4] = 5.18, p = 0.007; Figure 2.5A). For IL-1β mRNA expression, there 
was a main effect of LPS (F[1, 10] = 616.78, p < 0.0001), 5-aza (F[1, 10] = 26.73, p = 0.0004), 
and a 5-aza LPS interaction (F[1, 10] = 6.22, p = 0.032) with a 4-hour LPS treatment in that 5-
aza, and LPS produced a greater increase in IL-1β than 5-aza or LPS alone (Figure 2.5B). 
Similarly, for the 24-hour LPS treatment, there was a main effect of LPS (F[1, 10] = 89, p < 
0.0001), 5-aza (F[1, 10] = 25.7, p = 0.0005), and a 5-aza LPS interaction (F[1, 10] = 8.4, p = 
0.016) in that 5-aza, and LPS produced a greater increase in IL-1β than 5-aza or LPS alone, 
albeit less than at 4 hours (Figure 2.5C). In addition, primary microglial cells were cultured for 
7-8 days and treated with 5-aza for 24 hours and/or LPS for 4 hours. IL-1β promoter DNA 
methylation was decreased by 5-aza and LPS treatment (F[1, 10] = 26.27, p = 0.0004) and (F[1, 
10] = 22.6, p = 0.0008), and there was a 5-aza LPS interaction (F[1, 10] = 15.08, p = 0.003; 
Figure 2.6A). For IL-1β mRNA expression, there was a main effect of LPS (F[1, 9] = 652.96, p 
< 0.0001) and a main effect of 5-aza (F[1, 9] = 4.49, p < 0.063; Figure 2.6B). The increase in IL-
1β mRNA was numerically greatest when LPS and 5-aza were combined, but the 5-aza LPS 
interaction was not significant. We also assessed mRNA for genes involved in IL-1β signaling 
and processing in primary microglia (Table 2.2). For the 3 genes assessed, there was a main 
effect of LPS (F[1, 20] = 107.01, p < 0.0001; F[1, 20] = 324.97, p < 0.0001; and F[1, 20] = 
588.09, p < 0.0001 for Casp1, IL-1rn, and NLRP3, respectively), and for Casp1 and NLRP3, 
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there was a main effect of 5-aza (F[1, 20] = 3.55, p = 0.074 and F[1, 20] = 3.44, p = 0.079, 
respectively). No interactions were detected. These results suggest that several genes involved in 










Figure 2.5. Increased IL-1β gene expression in 5-aza, and LPS-treated BV-2 cells coincide with 
decreased IL-1β promoter DNA methylation. BV-2 cells were treated with 5-aza for 48 hours and/or LPS 
for 4 or 24 hours. Bars represent the mean ± standard error of the mean (n = 3-4). (A) IL-1β promoter 
DNA methylation as measured by a Methylation Index (MI). (B) IL-1β mRNA expression after 4 hours 
LPS treatment. (C) IL-1β mRNA expression after 24 hours LPS treatment. Treatment means with 
different letters are significantly different. Abbreviations: 5-aza, 5-azacytidine; IL-1β, interleukin-1 beta; 




Figure 2.6. Increased IL-1β gene expression in 5-aza, and LPS-treated primary cultured microglia 
coincide with decreased IL-1β promoter DNA methylation. Primary-cultured microglia were treated with 
5-aza for 24 hours and/or LPS for 4 hours. Bars represent the mean ± standard error of the mean (n = 3-4) 
for (A) IL-1β promoter DNA methylation as measured by a Methylation Index (MI) and (B) IL-1β 
mRNA expression. Treatment means with different letters are significantly different. Abbreviations: 5-
aza, 5-azacytidine; IL-1β, interleukin-1 beta; LPS, lipopolysaccharide.  
 
Table 2.2. Primary cultured microglia were treated with 5-aza for 24 hours and/or LPS for 4 hours. Data 
represent the mean ± standard error of the mean (n = 3-4). Key: 5-aza, 5-azacytidine; IL-1β, interleukin-1 
beta; LPS, lipopolysaccharide.  
2.5 Discussion 
The present study was designed to investigate a link between DNA methylation and the 
microglial phenotype of aged mice. We clearly demonstrated that age and LPS have the capacity 
to alter DNA methylation and expression levels of genes important for establishing, maintaining, 
or reversing DNA methylation in micro- glial cells. Of note, both aging and stimulation of the 
immune sys- tem with a proinflammatory agent (LPS) produces sickness behavior and decreases 
in methylation of the IL-1β promoter that coincide with increases in IL-1β gene expression and 
intracellular IL-1β production, suggesting that DNA methylation plays a role in the 
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overexpression of this proinflammatory cytokine with age. Although the percentage of IL-1β 
cells do not completely match previous findings (Henry et al., 2009), it is likely that our cell 
population is more highly purified now that the magnetic bead separation technique is used 
instead of the previous isolation method with a Percoll gradient (Burton, Rytych, Freund, & 
Johnson, 2013; Henry et al., 2009). Importantly, percentage of Cd11b+/CD45low cells is 
considerably higher with the new method (Maria Nikodemova & Watters, 2012).  
There are a number of possible mechanisms that could be mediating these alterations in 
DNA methylation with age and LPS. As nuclear factor-kB (NF-kB) activation is implicated in 
microglial aging (G. Zhang et al., 2013) and sickness behavior (Nadjar, Bluthe, May, Dantzer, & 
Parnet, 2005), NF-kB binding activity might play a role in demethylation of the IL-1β promoter. 
The site of methylation investigated in this study is adjacent to a canonical NF-kB-binding site 
(Lebedeva & Singh, 1997), and recently, the NF-kB subunit RelB at the IL-1β promoter was 
demonstrated to be required for the attenuated LPS response in LPS-preconditioned microglia 
(W. Schaafsma et al., 2015), thus providing evidence that epigenetic regulation of IL-1β in 
microglia from aged mice could be regulated by increased NF-kB binding that is inhibiting 
proper DNA methylation to be established. Further, it has been demonstrated that IL-1β induces 
its own expression in healthy chondrocytes and causes loss of DNA methylation (Hashimoto, 
Oreffo, Gibson, Goldring, & Roach, 2009). This has the potential to set up a dangerous positive 
feedback mechanism, and if true in vivo could partially explain the progression of 
neuroinflammation in aging. It should be stressed that additional studies are necessary to link 
these gene methylation and expression changes with histone alterations, subsequent behavioral 
outcomes, and to explore their reversibility.  
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Global DNA methylation was unchanged by age or LPS stimulation, suggesting that 
perhaps DNA hypomethylation is not a global phenomenon as it is in other cell types such as 
fibroblasts (Wilson & Jones, 1983). As epigenetic regulation of other proinflammatory genes 
such as tumor necrosis factor-a (TNF-a) and IL-6 have been demonstrated in other immune cell 
types such as natural killer cells and peripheral monocytes/macrophages (Eddy et al., 2014; 
Sullivan et al., 2007), it will be pertinent to explore regulation by DNA methylation and other 
epigenetic modifications in microglia, as well as other signature genes relevant to aging such as 
those recently found in the microglial sensome (Hickman et al., 2013) or other recent 
transcriptomic studies (Holtman et al., 2015; Orre et al., 2014).  
Gene expression of epigenetic regulators was found to be altered with age and LPS and 
support a number of previously established findings. DNMT3a and DNMT3b mRNA decreased 
with age, and these genes decrease with age in fibroblasts and T cells (Lopatina et al., 2002; Z. 
Zhang, Deng, Lu, & Richardson, 2002). LPS decreased DNMT3a expression, and this is 
consistent with a previous finding that LPS downregulates DNMT3a in calf peripheral blood 
mononuclear cells that occurred concurrently with high expression of proinflammatory genes 
(Doherty, O’Farrelly, & Meade, 2013). Further, as differences in DNMT3b expression have the 
ability to influence adipose tissue macrophage polarization, perhaps the microglial polarization 
seen in aging is acting through a similar mechanism (Yang et al., 2014). LPS decreased HDAC1 
expression and age also slightly decreased the expression at 4 hours (p < 0.1), but these results 
are more difficult to interpret based on existing literature. HDACs in general have been shown to 
be decreased with aging (Gravina & Vijg, 2010), but evidence has also shown that HDACs are 
increased with LPS in macrophages (Aung et al., 2006). It has been suggested that HDACs are 
important in limiting the inflammatory response as they have been reported to modulate Toll-like 
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receptor-mediated signaling and to inhibit NF-kB signaling (Aung et al., 2006), but inhibiting 
HDACs has also been demonstrated to suppress innate immune activation in microglia (Kannan 
et al., 2013). Additional work will be necessary to delineate these differential effects of HDACs 
in modulating inflammation, but nonetheless the current findings support the idea that decreased 
expression of corepressors like HDAC1 are associated with decreased IL-1β promoter DNA 
methylation.  
The significant decreases in MeCP2 with age are interesting considering a deficiency in 
MeCP2 has been widely associated with Rett syndrome, a neurodevelopmental disorder causing 
mental retardation with early onset in childhood, and MeCP2 mutant mice have been shown to 
exhibit many of the same cognitive deficits and neuroanatomical abnormalities associated with 
Rett syndrome (Guy, Hendrich, Holmes, Martin, & Bird, 2001). Intriguingly, selective return of 
MeCP2 function to microglia arrests Rett syndrome pathology (Derecki, Cronk, & Kipnis, 2013). 
The mechanism is unclear but may relate to phagocytic ability, as microglia from Mecp2-null 
mice had severe impairments in phagocytic ability in vitro. The authors proposed that 
insufficient clearance of debris within the brains of these animals might indeed contribute to the 
severity of pathology, and it seems that this same phenomenon could also be a mechanism 
involved in aging. Gadd45b was the only gene to increase with age, but expectedly so in that it 
plays a major role in DNA demethylation. Previous research has demonstrated that LPS, TNF, 
IL-6, and other inducers of oxidative stress can increase Gadd45b. Further, NF-kB can stimulate 
the expression of Gadd45 and simultaneously acts as its regulatory target, thus creating a positive 
feedback loop (Moskalev et al., 2012).  
As DNA hypomethylation is often described in context with gene activation, another 
important finding was to demonstrate that a demethylating drug like 5-aza has the capacity to 
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decrease IL-1β promoter DNA methylation and subsequently increase IL-1β mRNA in both BV2 
and primary microglia, establishing that DNA methylation does indeed play a direct role in IL-1β 
gene regulation. This also indicates that BV2 and cultured primary microglia have the capacity to 
display DNA methylation patterns in a manner consistent with what was seen in freshly isolated 
microglia (Fig. 2). This is important because primary microglia and cell lines in culture have 
been shown to lose their microglial signature (Butovsky et al., 2014; Gosselin et al., 2014). The 
exaggerated increase in IL-1β mRNA with both 5-aza and LPS in BV2 cells suggests that DNA 
hypomethylation allows LPS to trigger a more pronounced immune response and is in line with 
previous findings in other cell lines (Kovacs, Oppenheim, Carter, & Young, 1987; Wessels, 
Fleischer, Rink, & Uciechowski, 2010).  
It is also important to consider other factors that can lead to a heightened 
proinflammatory response with aging, such as expression of the endogenous receptor antagonist 
of IL-1β, IL-1ra (Spulber, Bartfai, & Schultzberg, 2009) or of inflammasomes (Goldberg & 
Dixit, 2015). As such, mRNA expression of several genes involved in IL-1β signaling and 
processing were also investigated in primary microglia treated with 5-aza or LPS. All IL-1β-
related genes were upregulated with LPS as expected, but 5-aza decreased Casp1 and NLRP3 
mRNA expression with or without LPS. This suggests that Casp1 and NLRP3 are additionally 
affected by DNA methylation but not in the same way as IL-1β. DNMT inhibitors in general 
create global demethylation of the genome, but there is some heterogeneity of response of loci 
(Pandiyan et al., 2013). Depending on cell type and site of methylation (e.g., promoter versus 
gene body methylation), DNA methylation and transcription can be positively correlated, or 
variable chromatin accessibility and constitutive DNA hypo- methylation can occur (Wagner et 
al., 2014). Histone modifications also have a close relationship with DNA methylation and could 
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be more influential on DNA methylation and transcription of some genes compared to others 
(Cedar & Bergman, 2009). More analyses of these genes involved in IL-1β signaling and 
processing will be necessary to understand their effects on microglial IL-1β with aging. 
However, the observation that 5-aza decreases IL-1β promoter DNA methylation and increases 
IL-1β mRNA expression (but not mRNA expression of all IL-1β signaling and processing genes) 
suggests that this is a specific relationship that could be important to understand the changes in 
IL-1β within the brain and specifically microglia from aged individuals.  
Although the increase in IL-1β mRNA with 5-aza and LPS was not significantly 
exaggerated when combined in primary cultured microglial cells, perhaps they are not capable of 
the same effects in culture and cannot perform in a similar manner in isolation without the 
influence of other cell types within the brain. Further, the techniques we used in this study do not 
allow us to draw any conclusions regarding cytosine methylation verses hydroxymethylation, 
subregion specificity, or site-specific methylation. In the future, it will be useful to use bisulfite 
pyrosequencing to characterize site-specific methylation changes of the IL-1β promoter.  
These findings highlight the importance of elucidating the interaction of the environment 
with the epigenome and its role in aging. Manipulating and understanding the epigenome holds 
promises for preventing and treating age-related diseases, such as restoring the DNA methylation 
profile of aging cells to that of young or mature cells and preventing significant age-associated 
demethylation. Specifically, a better understanding of how epigenetic mechanisms like DNA 
methylation become dysregulated with age in microglia is needed to improve our understanding 
of neuro- inflammatory complications and lead to the development of therapeutic interventions.  
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CHAPTER 3: INHIBITION OF DNA METHYLATION WITH ZEBULARINE ALTERS 
LIPOPOLYSACCHARIDE-INDUCED SICKNESS BEHAVIOR AND 
NEUROINFLAMMATION IN MICE 
3.1 Abstract  
 
Activity of DNA methyltransferases (DNMTs), the enzymes that catalyze DNA 
methylation, is dynamically regulated in the brain. DNMT inhibitors alter DNA methylation 
globally in the brain and at individual neural plasticity-associated genes, but how DNMT 
inhibitors centrally influence lipopolysaccharide (LPS)-induced neuroinflammation is not 
known. We investigated whether the DMNT inhibitor, zebularine, would alter sickness behavior, 
DNA methylation of the Il1b promoter and expression of inflammatory genes in hippocampus 
and microglia. Adult mice treated with an intracerebroventricular (ICV) injection of zebularine 
prior to LPS had faster recovery of burrowing behavior compared to mice treated with LPS. 
Further, genes of inflammatory markers, epigenetic regulators, and the microglial sensory 
apparatus (i.e. the sensome) were differentially expressed by zebularine alone or in combination 
with LPS. Bisulfite pyrosequencing revealed that ICV zebularine led to decreased DNA 
methylation of two CpG sites near the Il1b proximal promoter alone or in combination with LPS. 
Zebularine treated mice still exhibited decreased DNA methylation 48 h after treatment when 
LPS-induced sickness behavior as well as hippocampal and microglial gene expression were 
similar to control mice. Taken together, these data suggest that decreased DNA methylation, 
specifically of the Il1b promoter region, with a DNMT inhibitor in brain disrupts molecular 





3.2 Introduction  
Microglia are long-lived resident immune cells of the brain that show limited turnover (R. 
M. Ransohoff & Perry, 2009). They develop early in embryogenesis in the embryonic yolk sac 
and migrate to the central nervous system (CNS) where they remain and are rarely replaced 
(Ginhoux et al., 2010). Microglia are far from inactive and many recent in vivo observations have 
shown that microglia extend their processes to actively scan the microenvironment (Nimmerjahn 
et al., 2005; Wake et al., 2009). Despite the dynamic role of microglia in maintaining 
homeostasis, their long-lived nature and general inability to be replaced by circulating peripheral 
cells makes them particularly sensitive to oxidative stress, DNA damage, and a lifetime of 
inflammatory insults. Peripheral macrophage subtypes express different patterns of genes after 
stimulation with LPS that is linked to environmental influence of distinct epigenetic 
modifications during their differentiation (Kittan et al., 2013). However, little is known about the 
epigenetic pathways involved in the modulation of inflammatory genes in the brain and 
microglia. As the immune system needs to respond to rapidly changing environmental cues, the 
molecular regulation of inflammatory responses in the brain is also a likely target for epigenetic 
regulation (Garden, 2013).  
DNA methylation of pro-inflammatory cytokines such as Il1b is a mechanism that 
regulates microglial reactivity and could be a therapeutic target for regulating microglia 
throughout the lifespan. One particularly important study determined that sirtuin 1 deficiency in 
aging microglia is associated with increased Il1b transcription and decreased methylation of CpG 
sites within the Il1b proximal promoter (Cho et al., 2015). More recently, findings from our lab 
(Matt, Lawson, & Johnson, 2016) indicated that aged mice had decreased methylation of the Il1b 
gene promoter in primary microglia basally or following systemic LPS that is associated with 
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increased Il1b mRNA. Further, the DNMT inhibitor 5-azacytidine increased Il1b gene 
expression and decreased DNA methylation of primary microglial cells.  
DNA methylation and demethylation are dynamically regulated in the brain 
(Kundakovic, Chen, Guidotti, & Grayson, 2009; Roth, Lubin, Funk, & Sweatt, 2009), and it has 
been demonstrated that DNA methylation changes can happen in as quickly as one hour (Miller 
& Sweatt, 2007). The reversible nature of epigenetic aberrations contributing to human diseases 
makes them desirable therapeutic targets. 5-aza-2′-deoxycytidine and 5-azacytidine are DNMT 
inhibitors that are potential chemotherapeutic agents for cancer, and have been approved for 
treating myelodysplastic syndrome (Copeland, Olhava, & Scott, 2010). Both drugs act by 
incorporating into DNA where they bind and sequester DNMTs, which causes prevention of the 
maintenance methylation (Gnyszka, Jastrzebski, & Flis, 2013). However, both compounds are 
chemically unstable and toxic. Zebularine is a stable nucleoside analog of cytidine that is a less 
toxic DNMT inhibitor and the first drug in its class that can reactivate an epigenetically silenced 
gene by oral administration (Cheng et al., 2003). Moreover, zebularine is comparable to 5-aza-2′-
deoxycytidine and 5-azacytidine in terms of its pattern of DNA demethylation (Balch et al., 
2005; Griffin, Niederhuth, & Schmitz, 2016). 
A significant amount of research has utilized ICV zebularine injections in rodent models, 
such as a cocaine-induced behavioral sensitization model (Anier, Malinovskaja, Aonurm-Helm, 
Zharkovsky, & Kalda, 2010), and an ischemic brain injury model (Dock, Theodorsson, & 
Theodorsson, 2015), to determine the relationship between DNA methylation status and disease. 
Since DNMT inhibition was able to demethylate the Il1b gene promoter and subsequently 
increase Il1b gene expression in vitro (Matt et al., 2016), the objectives of this study were to 
investigate whether central DNMT inhibition by zebularine causes exaggerated 
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neuroinflammation in microglia and hippocampus. We hypothesized that central DNMT 
inhibition would lead to decreased Il1b DNA methylation and heightened pro-inflammatory gene 
expression in adult mice as well as prolonged sickness behavior following central immune 
stimulation with LPS. Additionally, with the recent discovery of the microglial sensome 
(Hickman et al., 2013), a unique group of transcripts encoding proteins for sensing endogenous 
ligands and microbes, we hypothesized zebularine would alter genetic expression of sensome 
genes in microglia. Last, since DNA methylation affects other epigenetic processes such as 
histone modifications (Fuks, 2005), we predicted zebularine would change expression of 
epigenetic regulator genes within microglia.  
3.3 Methods 
Animals 
Adult (3-6-month-old) male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, 
USA) were individually housed in a temperature-controlled environment with a 12-hour 
reversed-phase light/dark cycle (lights on 21:00h). Mice were allowed to acclimate to these 
conditions for at least 3 weeks before being stereotaxically implanted with a guide cannula 
(Plastics One, Roanoke, VA, USA) placed to extend 1 mm dorsal to the lateral ventricle, as 
previously described (M. A. Lawson et al., 2013). In brief, mice were deeply anesthetized with 
an intraperitoneal (IP) injection of ketamine, xylazine, and buprenorphine (100, 10, and 0.05 
mg/kg, respectively) all at 100µl/10g body weight and the surgical site was shaved and sterilized. 
Cannulae were placed at 1.5 mm lateral, 0.6 mm posterior, and 1.3 mm dorsal with respect to 
bregma. Guide cannulae were kept clean and covered using a screw-on dummy cannula (Plastics 
One). Mice were given 7 days to recover from surgery prior to ICV injections. All studies were 
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carried out in accordance with United States National Institutes of Health guidelines and 
approved by the University of Illinois Institutional Animal Care and Use Committee. 
Treatments were designed in a 2 x 2 factorial arrangement and administered at the onset 
of the dark cycle. ICV injections were administered using a 10 µl gas-tight syringe attached to 
internal injector cannulae (Plastics One) that extended 1 mm beyond the tip of the guide cannula, 
thus penetrating the lateral ventricle. All mice received treatments in 1 µl injection volume over a 
1-minute time period followed by an additional 1-minute delay to allow diffusion before 
removing the injector cannula. Mice were injected ICV with either saline (control) or 300ng/µl of 
zebularine (Sigma Aldrich, St Louis, MO, USA) and 30 minutes later with saline or LPS 
(10 ng/µl) from Escherichia coli O127:B8 (Sigma Aldrich). This dose of LPS has been 
previously demonstrated to induce transient sickness behavior (Huang, Henry, Dantzer, Johnson, 
& Godbout, 2008). 
Burrowing behavior  
Decreased burrowing behavior is an indicator of sickness behavior (McLinden et al., 
2012). Using a similar procedure described previously (Moon et al., 2015), burrows were 
constructed of polyvinyl chloride (PVC) pipe fitted at one end with a PVC pipe cap (closed end). 
The open end was raised 1.3 cm on twin steel legs. To acclimatize mice to the burrow, mice were 
singly housed in cages with the burrow present for 24 hours prior to testing. Testing was initiated 
by adding 200 g of food pellets (Harlan Teklad 8640 chow, Madison, WI, USA) to the burrow 
immediately after the LPS/saline injections. Prior to replacing the burrow filled with food back 
into the cage, the burrow and food was weighed. Water was provided ad libitum but food was 
only available from the burrow. Mice were allowed to dig and/or eat the food out of the burrow 
for 48 h. Amount burrowed was calculated by subtracting the burrow and food weight before and 
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4, 8, 12, 24, and 48 hours after burrowing. Body weight was also measured at baseline and 4, 8, 
12, 24, and 48 hours after the LPS/saline injections.  
Microglia isolation 
Microglia from mouse brains were isolated from separate groups of mice at 4 hours and 
48 hours after treatment. Mice were euthanized via CO2 asphyxiation, perfused with sterile ice-
cold saline, and brain tissue (all but the hippocampus which was frozen on dry ice) was collected 
and used immediately for microglia isolation using a procedure adapted from Nikademova & 
Watters (Maria Nikodemova & Watters, 2012). Brains were enzymatically digested using the 
Neural Tissue Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) for 35 min at 37° 
C. Further processing was performed at 4° C. Tissue debris was removed by passing the cell 
suspension through a 40 µm cell strainer. After myelin removal using 30% Percoll Plus (GE 
Healthcare, Princeton, NJ, USA), cells in PBS supplemented with 0.5% BSA and 2 mM EDTA 
were incubated for 15 minutes with anti-Cd11b magnetic beads (Miltenyi Biotec). CD11b+ cells 
were extensively washed and separated in a magnetic field using MS columns (Miltenyi Biotec) 
before being directly placed in Trizol reagent (Invitrogen, Carlsbad, CA, USA). 
RNA isolation and real-time RT-PCR 
Total RNA from microglia and hippocampal tissue was isolated using the Tri Reagent 
protocol (Invitrogen). Synthesis of cDNA was carried out using a high-capacity RT kit (Applied 
Biosystems, Grand Island, NY, USA) according to the manufacturer’s instructions. Real-time 
RT-PCR was performed on an ABI PRISM 7900HT-sequence detection system (Perkin Elmer, 
Forest City, CA, USA). All genes were analyzed using commercially validated PrimeTime real-
time RT-PCR Assays included in Table 1 (Integrated DNA Technologies, Coralville, IA, USA), 
and were compared with the housekeeping control gene Gapdh using the 2−ΔΔCt calculation 
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method as previously described (Livak & Schmittgen, 2001). Data are expressed as fold change 
versus controls.  
Fluidigm  
Total RNA from microglia collected at 4 hours was isolated using the Tri Reagent 
protocol (Invitrogen) and synthesis of cDNA was carried out using a high-capacity RT kit 
(Applied Biosystems) as previously described for real-time RT-PCR. Fluidigm reactions were 
performed by the UIUC Functional Genomics Unit of the W.M. Keck Center using a 96 × 96 
chip and included 2 technical replicates for each combination of sample and assay. Data was 
acquired using the Fluidigm Real-Time PCR Analysis software 3.0.2 (Fluidigm, San Francisco, 
CA, USA). Data from Fluidigm runs were manually checked for reaction quality before analysis, 
and Ct values for each gene target (see Table 3.1) were normalized to Ct values for the 
housekeeping gene Gapdh.  
Table 3.1. Primers used in Real-time RT-PCR and Fluidigm experiments. 
 
















































Table 3.1 (cont.). Primers used in Real-time RT-PCR and Fluidigm experiments. 
 
DNA Isolation and Pyrosequencing  
Total DNA from microglia and hippocampal tissue collected at both 4 and 48 hours was 
isolated using the Tri Reagent protocol (Invitrogen). DNA methylation for 2 CpG sites within the 
proximal promoter region of Il1b was assessed via bisulfite pyrosequencing on bisulfite modified 
DNA (Zymo Research, Irvine, CA, USA). Mouse Il1b methylation assays (ID ADS3713-RS1) 
were purchased from EpigenDx (Hopkinton, MA, USA) and have been previously used to assess 
methylation status in microglia (Cho et al., 2015). PCRs were run in duplicate and contained 
20 ng of bisulfite converted DNA as starting template. Product specificity was determined by gel 
electrophoresis. Each primer was also tested using bisulfite converted DNA from high and low 
methylation controls (EpigenDx). Qiagen's PyroMark Q24 Advanced Pyrosequencer was used to 
detect DNA methylation levels following manufacturer's protocols and default settings (Qiagen, 






All data were analyzed using GraphPad Prism 7 (La Jolla, CA, USA). Behavior and 
change in body weight data were analyzed via a two-way repeated-measures analysis of variance 
(ANOVA) for main effects of zebularine and LPS, and all two-way interactions. Gene 
expression and pyrosequencing data from primary microglia and hippocampus were subjected to 
a two-way ANOVA (no repeated measures) for main effects of zebularine and LPS, and all two-
way interactions. Where analysis of variance revealed a significant interaction (p<0.05 unless 
noted elsewhere), Tukey’s test was used for post hoc comparisons when appropriate. All data are 
expressed as means ± SEM.  
3.4 Results 
Body weight decreases with LPS in both saline and zebularine pre-treated mice 
Mice were either pre-treated ICV with saline or zebularine (ZEB), and then given an ICV 
injection of either saline (SAL) or LPS. For body weight, two way repeated measures ANOVA 
revealed main effects of both ZEB (p<0.0001) and LPS (p<0.0001), and an interaction (ZEB x 
LPS; p<0.0001) (Figure 3.1A). Post-hoc tests revealed that at 4 hours, all treatment groups were 
not different (p>0.05). At 8 and 12 hours, the SAL+SAL group was different from SAL+LPS 
(p=0.0002 and p=0.0005) and ZEB+LPS (p=0.0006 and p<0.0001), and the ZEB+SAL group 
was also different from SAL+LPS (p<0.0001 and p<0.0001) and ZEB+LPS (p<0.0001 and 
p<0.0001), in that the SAL+LPS and ZEB+LPS groups lost more weight than the SAL+SAL and 
ZEB+SAL groups. At 24 hours, the results were similar but the ZEB+LPS group was no longer 
different than the SAL+SAL group (p=0.0651). By 48 hours, body weight of the LPS-treated 




Zebularine pre-treated mice recover faster from central LPS-induced sickness  
For burrowing behavior, two way repeated measures ANOVA revealed main effects of 
both ZEB (p<0.0001) and LPS (p<0.0001), and an interaction (ZEB x LPS; p<0.0001) (Figure 
3.1B). Post-hoc tests revealed that at 4 and 8 hours, the SAL+SAL group was different from 
SAL+LPS (p<0.0001 and p<0.0001) and ZEB+LPS (p=0.0474 and p<0.0001), and the 
ZEB+SAL group was also different from SAL+LPS (p<0.0001 and p<0.0001) and ZEB+LPS 
(p=0.006 and p<0.0001), in that the SAL+LPS and ZEB+LPS groups burrowed less than the 
SAL+SAL and ZEB+SAL groups. At 12 and 24 hours, the results were similar but the ZEB+LPS 
group was now different than the SAL+LPS group (p=0.0071 and p=0.0126), in that the 
ZEB+LPS was burrowing more. By 48 hours, all of the mice burrowed out the majority of the 
food and treatment groups did not differ from one another (p>0.05). 
 
Figure 3.1. (A) Body weight was measured at baseline and 4, 8, 12, 24, and 48 hours after SAL/LPS ICV 
injections in adult mice pre-treated with ICV SAL/ZEB. Data are presented as means ± SEM (n=7-9). (B) 
Burrowing behavior was measured at 4, 8, 12, 24, and 48 hours after SAL/LPS ICV injections in adult 
mice pre-treated with ICV SAL/ZEB. Data are presented as means ± SEM (n=7-9). * indicates 






Zebularine alters LPS-induced expression of inflammatory, sensome, and epigenetic 
regulator genes  
Fluidigm gene expression analysis on microglia was performed to gain a more 
comprehensive assessment of microglial gene regulation in response to zebularine. For 
inflammatory and regulators of inflammatory genes, there were a number of significant 
interactions in that ZEB decreased LPS-induced gene expression (Il1b, Il-1rn, Il-10, Nlrp3, 
Socs1, Tlr2, Tnf) (Table 3.2A). For sensome genes, there were no interactions of ZEB and LPS, 
but all were significantly or nearly significantly impacted by LPS, in that there were decreases 
compared to controls (Table 3.2B). Further, there were a few genes impacted by ZEB (P2ry12, 
Siglech, Tgfbr1) in that there were also decreases in gene expression. For epigenetic regulator 
genes, some Dnmts decreased as expected (Dnmt3a, Dnmt3b), and Hdacs responded differently 
independently of HDAC family (i.e. Hdac2, 3, 4, and 5 had significant effects of LPS while 
Hdac1 had a very significant effect of ZEB) (Table 3.2C). Of note, some epigenetic regulator 
genes were affected slightly different in the SAL+LPS group compared to what has been 
demonstrated with LPS IP injections in adults (Dnmt1, Dnmt3b, Hdac1, Mecp2) (Matt et al., 
2016). For epigenetic regulators partially responsible for DNA demethylation, Gadd45b 
increased with LPS as expected, but was decreased by zebularine and there was an interaction 
that zebularine decreased LPS-induced expression. For gene expression of the Tet proteins, 
which are responsible for DNA hydroxymethylation and influencing DNA demethylation (Kohli 
& Zhang, 2013), Tet1 and Tet2 were effected by LPS and zebularine but LPS decreased Tet1 and 




ICV zebularine decreases methylation at CpG 1 and 2 of the Il1b promoter in microglia at 
4 hours 
DNA methylation for two CpG sites within the proximal promoter region of Il1b was 
assessed via bisulfite pyrosequencing. These two sites were chosen because they have been 
shown to be dynamically regulated in a previous study (Cho et al., 2015). For CpG 1, main effect 
of ZEB (p=0.0206), in that ZEB decreased DNA methylation (Figure 3.2C). For CpG 2, there 
was also a main effect of ZEB (p=0.0228), in that zebularine decreased methylation (Figure 






Figure 3.2. (A) Heat map visualization of relative expression (fold change) of genes in microglia 
analyzed by Fluidigm. Microglia were collected at 4 hours after SAL/LPS ICV injections in adult mice 
pre-treated with ICV SAL/ZEB. (B) Mouse Il1b promoter. DNA methylation of the Il1b promoter in 
microglia at (C) CpG1 and (D) CpG2. Data are presented as means ± SEM (n=7-9). Abbreviations: S+L, 
SAL+LPS; S+S, SAL+SAL; TSS, transcription start site; Z+L, ZEB+LPS; Z+S, ZEB+SAL. * indicates a 















Table 3.2. Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in microglia 
collected at 4 hours after SAL/LPS ICV injections in adult mice pre-treated with ICV SAL/ZEB. Data are 
presented as means ± SEM (n=5-7) and p-values for main effects of ZEB and LPS as well as ZEB x LPS 
interactions are also included. 
 
A. Inflammatory and Regulators of Inflammatory Genes 
 p-values 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Arg1 1.05±0.32 0.88±0.22 1.80±0.71 2.96±0.85 0.467 0.046* 0.332 
Casp1 1.16±0.08 0.72±0.05 0.88±0.06 0.84±0.07 0.001* 0.236 0.006* 
Cd68 0.94±0.08 0.92±0.13 0.52±0.05 0.92±0.13 0.719 <0.0001* 0.567 
Cx3cr1 1.08±0.05 0.86±0.07 0.48±0.08 0.42±0.08 0.056 <0.0001* 0.305 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Il-1β 1.08±0.24 1.05±0.14 9.31±2.18 3.46±0.88 0.012* <0.0001* 0.013* 
Il-1rn 0.98±0.41 2.46±0.68 39.00±8.37 8.86±0.68 <0.0001* <0.0001* <0.0001* 
Il-10 0.97±0.17 0.70±0.06 7.92±1.66 3.53±0.96 0.021* <0.0001* 0.040* 
Il-4 1.23±0.47 1.72±0.32 3.04±0.94 2.57±0.52 0.994 0.072 0.504 
Il-6 1.14±0.15 0.89±0.09 10.31±1.71 5.38±1.20 0.034* <0.0001* 0.055 
Nlrp3 1.00±0.18 0.66±0.06 3.74±0.97 1.75±0.34 0.022* 0.0004* 0.098 
Pycard 0.99±0.06 0.75±0.02 0.61±0.07 0.68±0.03 0.097 <0.0001* 0.004* 
Socs1 0.99±0.13 0.93±0.08 3.66±0.46 1.37±0.23 <0.0001* <0.0001* <0.0001* 
Socs3 0.92±0.13 0.58±0.06 2.33±0.30 1.27±0.27 0.003* <0.0001* 0.11 
Stat3 1.10±0.09 0.81±0.06 1.91±0.22 1.43±0.18 0.016* <0.0001* 0.534 
Tlr2 0.98±0.07 0.89±0.07 2.25±0.29 1.32±0.16 0.004* <0.0001* 0.016* 
Tlr4 1.12±0.07 0.89±0.07 0.80±0.06 0.76±0.04 0.035* 0.0005* 0.136 
Tlr7 1.11±0.09 0.72±0.03 0.64±0.04 0.72±0.05 0.011* 0.0002* 0.0003* 
Tlr8 0.90±0.19 0.69±0.12 0.80±0.12 1.28±0.17 0.414 0.133 0.038* 
Tnf 1.01±0.17 0.84±0.11 3.86±0.58 1.54±0.28 0.0004* <0.0001* 0.002* 
 
B. Sensome Genes 
     p-values 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Cd53 1.01±0.18 0.92±0.19 0.70±0.06 0.68±0.16 0.738 0.081 0.8135 
Gpr34 1.04±0.04 0.88±0.05 0.40±0.09 0.39±0.14 0.386 <0.0001* 0.447 
P2ry12 1.14±0.09 0.78±0.08 0.49±0.09 0.41±0.12 0.035* <0.0001* 0.17 
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P2ry13 1.03±0.07 0.85±0.07 0.61±0.09 0.51±0.09 0.0787 <0.0001* 0.657 
Siglech 1.18±0.07 0.84±0.08 0.65±0.08 0.49±0.08 0.003* <0.0001* 0.278 
Tgfbr1 1.03±0.08 0.77±0.05 0.55±0.09 0.42±0.08 0.016* <0.0001* 0.408 
Tmem119 1.07±0.17 0.95±0.13 0.45±0.10 0.48±0.11 0.726 0.0003* 0.601 
Trem2 0.92±0.13 0.77±0.20 0.40±0.07 0.39±0.10 0.541 0.001* 0.586 
 
C. Epigenetic Regulator Genes 
     p-values 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Dnmt1 1.00±0.18 0.53±0.14 0.24±0.09 0.52±0.14 0.524 0.012* 0.013* 
Dnmt3a 1.17±0.13 0.92±0.04 0.72±0.13 0.62±0.07 0.041* <0.0001* 0.369 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Dnmt3b 1.17±0.10 0.66±0.06 0.73±0.20 0.72±0.09 0.044* 0.142 0.049* 
Dnmt3l 1.10±0.33 0.64±0.11 0.61±0.16 0.74±0.13 0.397 0.324 0.137 
Gadd45b 0.91±0.11 0.46±0.10 3.46±0.79 1.44±0.21 0.009* 0.0002* 0.015* 
Hdac1 1.17±0.11 0.84±0.06 1.36±0.18 0.82±0.04 0.0002* 0.42 0.317 
Hdac2 1.16±0.15 0.78±0.10 0.58±0.07 0.69±0.11 0.253 0.006* 0.041* 
Hdac3 1.15±0.07 0.90±0.07 0.71±0.04 0.77±0.06 0.151 <0.0001* 0.015* 
Hdac4 1.01±0.26 1.41±0.26 2.14±0.44 2.00±0.28 0.685 0.009* 0.39 
Hdac5 0.95±0.16 0.92±0.18 0.49±0.09 0.49±0.11 0.921 0.003* 0.909 
Hdac6 0.94±0.11 0.87±0.14 0.63±0.13 0.78±0.10 0.737 0.11 0.365 
Mecp2 1.10±0.07 0.83±0.04 0.90±0.05 0.83±0.04 0.002* 0.071 0.054 
Tet1 1.29±0.12 0.83±0.07 0.38±0.08 0.31±0.11 0.052 <0.0001* 0.2 
Tet2 1.00±0.10 0.73±0.05 1.52±0.21 1.06±0.12 0.007* 0.002* 0.484 
Tet3 0.92±0.20 0.98±0.23 0.7±0.21 1.07±0.33 0.496 0.836 0.615 
 
Table 3.2 (cont.). Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in 
microglia collected at 4 hours after SAL/LPS ICV injections in adult mice pre-treated with ICV 
SAL/ZEB. Data are presented as means ± SEM (n=5-7) and p-values for main effects of ZEB and LPS as 






Zebularine altered LPS-induced expression of inflammatory genes and Il1b promoter 
methylation in the hippocampus at 4 hours 
In the hippocampus (Figure 3.3), for Il1b, there were main effects of LPS (p=0.001), 
ZEB (p=0.0445), and an interaction (p=0.0464) in that ZEB decreased LPS-induced Il1b 
expression. The same changes were observed for Tnf, with main effects of LPS (p<0.0001), ZEB 
(p=0.0362), and an interaction (p=0.0384). For Il-6, there was only a main effect of LPS 
(p=0.0005). For Il-10, main effects of LPS (p=0.0016), ZEB (p=0.0437), and an interaction 
(p=0.0457) in that ZEB increased LPS-induced Il-10 expression. For Cx3cr1, no significant 
effects were observed. For Gfap, main effects of LPS (p=0.0006), ZEB (p=0.033), and a trending 
interaction (p=0.0815) in that ZEB increased LPS-induced Gfap expression. Increased 
expression with ZEB and LPS was also seen for Socs3 (LPS (p<0.0001), ZEB (p=0.0318), and a 
trending interaction (p=0.0591)) and for Stat3 (LPS (p<0.0001), ZEB (p=0.0083), and an 
interaction (p=0.0347)). With regards to DNA methylation, for Il1b CpG 1, there was a main 
effect of LPS (p=0.0011), in that LPS decreased DNA methylation. For Il1b CpG 2, there was a 
main effect of ZEB (p=0.0355), in that zebularine decreased methylation, and trending effect of 












Figure 3.3. Hippocampal gene expression and DNA methylation at 4 hours after SAL/LPS ICV 
injections in adult mice pre-treated with ICV SAL/ZEB. Data are presented as means ± SEM (n=7-9) for 
(A) Il1b, (B) Tnf, (C) Il-6, (D) Il-10, (E) Cx3cr1, (F) Gfap, (G) Socs3, and (H) Stat3 gene expression. 
Data are presented as means ± SEM (n=7-9) for DNA methylation of the Il1b promoter in hippocampus at 
(I) CpG1 and (J) CpG2. Treatment means with different letters are significantly different. * indicates a 
main effect with significance at p<0.05. 
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No effect of zebularine on inflammatory gene expression at 48 hours in microglia and 
hippocampus, but DNA methylation changes still present 
Only main effects of LPS were observed at 48 hours in both microglia and hippocampus (Figure 
3.4). For microglia, Il1b and Il-6 had main effects of LPS ((p<0.0001) and (p<0.001)). For 
hippocampus, Il1b and Tnf had main effects of LPS ((p=0.0052) and (p=0.0346)). For Il1b DNA 
methylation, in microglia, Il1b CpG1 main effects of ZEB and LPS (p=0.0186 and p=0.0484) 
and Il1b CpG2 main effects of ZEB and LPS (p=0.0005 and p=0.0021) in that ZEB and LPS 
decreased DNA methylation. For hippocampus, Il1b CpG1 trending main effect of LPS 





Figure 3.4. Gene expression and DNA methylation of microglia and hippocampus at 48 hours after 
SAL/LPS ICV injections in adult mice pre-treated with ICV SAL/ZEB. Data are presented as means ± 
SEM (n=7-9) for microglial (A) Il1b, (B) Tnf, (C) Il-6, and hippocampal (D) Il1b, (E) Tnf, and (F) Il-6. 
Data are presented as means ± SEM (n=7-9) for DNA methylation of the Il1b promoter in microglia at 
(G) CpG1 and (H) CpG2 and in hippocampus at (I) CpG1 and (J) CpG2. * indicates a main effect with 
significance at p<0.05. 
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3.5 Discussion  
The present study was designed to investigate a link between DNA inhibition and 
neuroinflammation. We hypothesized that central administration of LPS and zebularine in adult 
mice would cause an exacerbated neuroinflammatory response, in that there would be 
exaggerated sickness behavior and a pro-inflammatory gene expression profile that would be 
associated with DNA demethylation of Il1b. Surprisingly, instead of intensifying the LPS-
induced sickness response and increasing inflammation in the brain, zebularine led to a quicker 
recovery of LPS-induced sickness behavior and decreased cytokine gene expression. Results of 
the Fluidigm analysis indicated that DNMT inhibition created an anti-inflammatory profile in 
microglia at 4 hours, as many inflammatory genes were decreased by zebularine alone or in 
combination with LPS (Il1b, Tnf, etc.). Although these results do not support the original 
hypothesis that pharmacological DNMT inhibition in the context of central immune activation 
causes an exaggerated cytokine response within the adult brain, similar to what has been seen in 
vitro, studies have demonstrated that DNMT inhibitors have an immunosuppresive effect in 
other cell types. Human mesenchymal stem cells treated with a DNMT inhibitor had increased 
inhibitory effects on mononuclear cell proliferation and cell migration toward activated T cells, 
and when injected IP into mice they had a therapeutic effect in a DSS-induced mouse colitis 
model (Lee et al., 2015). Further, there is some indication that such anti-inflammatory effects of 
these drugs could translate to human disease, as patients with acute myeloid leukemia who were 
treated with a DNMT inhibitor after allogeneic stem cell transplantation were shown to have 
increased numbers of regulatory T cells, which was associated with a low incidence of graft-
versus-host disease (Goodyear et al., 2012).  
Novel findings using the Fluidigm analysis indicated differential expression of epigenetic 
regulators and sensome genes in microglia with central zebularine and LPS. Nearly all Hdacs 
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analyzed were affected by LPS, a response that has been demonstrated elsewhere (Kannan et al., 
2013). Further, Hdac1’s significant downregulation with zebularine supports the dependency of 
HDAC regulation on DNA methylation (Fuks, 2005).  Of note, altered gene expression of Tet 
proteins, which has been explored very little in microglia, indicate a role of DNA 
hydroxymethylation in response to DNMT inhibition and LPS. To support this, it has recently 
been found that Tet2 is implicated in the regulation of cytokine expression during innate as well 
as T-cell-mediated immune responses, and that this is controlled by an HDAC-dependent 
mechanism (Q. Zhang et al., 2015). Similarly, Tet2 deficiency induced in CD2+ T cells is 
associated with aberrant cytokine production and leads to increased autoimmunity in a mouse 
model of human multiple sclerosis (Ichiyama et al., 2015). Further, for the majority of microglial 
sensome genes analyzed, they decreased with zebularine and/or LPS. As it has been 
demonstrated that these same genes are downregulated with aging and that it would be 
conceptually beneficial to the brain to downregulate the ability of microglia to get activated by 
dying or injured cells with aging (Hickman et al., 2013), reproducing this neuroprotective 
phenotype with DNMT inhibition during LPS-induced inflammation could indicate therapeutic 
potential in other inflammatory diseases.  
Expression of inflammatory genes in the hippocampus at 4 hours predominantly mirrored 
the anti-inflammatory changes in microglia. This included decreases in Il1b and Tnf and 
increases in Socs3 and Stat3 in mice given both zebularine and LPS. There was an opposite 
effect of zebularine and LPS on Il-10 expression, but this could be explained by the increases in 
Gfap expression. Increases in Gfap could indicate increased astrocyte activation and modulation 
of microglia within heterogeneous brain tissue (Lobo-Silva, Carriche, Castro, Roque, & Saraiva, 
2016; Villacampa et al., 2015). Additional studies would be useful in identifying other cell 
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populations such as astrocytes within the brain that are altered with DNMT inhibition during 
immune activation.  
One particularly interesting finding was that although the effect of zebularine on gene 
expression disappeared at 48 hours, DNA methylation changes were still present. In fact, even 
more changes were present in microglia at 48 hours than at 4 hours. The functions of DNA 
methylation in the brain have predominantly been investigated by exploring instances where 
changes in methylation within gene promoters correlate with changes in gene expression. Cases 
where basal levels of gene expression remain unaltered following a change in DNA methylation 
within the corresponding gene have been largely overlooked, which has led to a limited 
appreciation of the functional variations in DNA methylation across the genome (Baker-
Andresen, Ratnu, & Bredy, 2013; Wagner et al., 2014). However, the relationship between DNA 
methylation and transcriptional activity is more complex than previously realized, such as the 
recent discovery of hydroxymethylation or that DNA methylation can regulate alternative 
splicing, the development of bivalent chromatin marks, or direct nucleosome repositioning. The 
relevance of this expanded repertoire of epigenomic modifications, particularly within the 
context of microglial development and activation across the lifespan, remains to be determined. 
Such epigenetic modifications may persist and alter the subsequent response to immune 
stimulation, thus providing a form of innate cell ‘memory’ that can contribute to a relatively 
nonspecific resistance to re-infection — a phenomenon that has been termed ‘trained immunity’ 
(Netea et al., 2016). Experience-dependent variations in DNA methylation such as infection may 
prime the genome for response to later events by regulating transcription in response to incoming 
inputs, rather than by mediating enduring changes in gene expression.  
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In conclusion, these data do support the hypothesis that epigenetic mechanisms like DNA 
methylation modulate neuroinflammatory responses. Perhaps the most exciting conclusion to be 
drawn from this work is that modulation of DNA methylation may influence not only the 
molecular features, but can also affect behavioral outcomes in animals. Pharmacological 
strategies aimed at specifically decreasing exacerbated microglial reactivity associated with 
infection might be important for improving recovery from sickness and reducing 
neurobehavioral deficits in populations like the elderly. More precise selectivity of epigenetic 
drugs is increasing, and with the recent generation of small-molecule inhibitors for multiple 
classes of histone modifiers, we will be better able to explore epigenetic proteins and uncover 
selective roles in the regulation of gene expression (Tough, Lewis, Rioja, Lindon, & Prinjha, 
2014; Tough, Tak, Tarakhovsky, & Prinjha, 2016). The capacity of these compounds to 
selectively modify gene expression and to modulate pro-inflammatory responses indicates great 













CHAPTER 4: BUTYRATE AND DIETARY SOLUBLE FIBER IMPROVE 
NEUROINFLAMMATION ASSOCIATED WITH AGING IN MICE 
4.1 Abstract 
It is well accepted that aging results in chronic systemic inflammation that can alter 
neuroinflammation in the brain. Specifically, microglia shift to a pro-inflammatory phenotype 
that make them hypersensitive to signals from the peripheral immune system. It is proposed that 
certain nutrients can manipulate the epigenome to delay brain aging by preventing or reversing 
microglial aging. Butyrate, a short-chain fatty acid (SCFA) produced by bacterial fermentation of 
fiber in the colon, has been extensively studied pharmacologically as a histone deacetylase 
(HDAC) inhibitor, which has become an attractive therapeutic candidate. It is still not fully 
understood however, if an increase in butyrate-producing bacteria in the gut as a consequence of 
soluble fiber diet, could affect microglial activation, and specifically microglial activation in 
aging. Adult and aged mice were fed either a 1% low cellulose (non-fermentable fiber) or 5% 
high inulin (fermentable fiber) diet for 4 weeks. Findings indicate that mice fed inulin had an 
altered gut microbiome and increased butyrate, acetate, and total SCFA production. In addition, 
gene expression of inflammatory markers, epigenetic regulators, and the microglial sensory 
apparatus (i.e. the sensome) were altered by both diet and age, in that aged animals had a more 
anti-inflammatory microglial profile on the high fiber diet. Further, histological scoring of the 
distal colon demonstrated that aged animals on the low fiber diet had increased inflammatory 
infiltrate that was significantly decreased with the high fiber diet. Taken together, high fiber 
supplementation in the elderly is a non-invasive strategy to increase butyrate levels, and these 
data suggest that an increase in butyrate through added soluble fiber such as inulin could 




During normal healthy aging, there is a disruption in the communication and balance 
between the brain and immune system. Microglia shift to a proinflammatory phenotype that 
make them hypersensitive to signals from the peripheral immune system (DiSabato, Quan, & 
Godbout, 2016; Matt & Johnson, 2016). The precise mechanisms during aging that are 
responsible for this detrimental transition is not known, but overproduction of IL-1β has been 
shown to play a role. Recently, we demonstrated that aged mice had decreased methylation of 
the pro-inflammatory cytokine interleukin (IL)-1β gene promoter in primary microglia basally or 
following systemic lipopolysaccharide (LPS) that is associated with increased Il1b mRNA (Matt 
et al., 2016). This is critical because overproduction of IL-1β has been demonstrated to produce 
cognitive dysfunction in rodent models (Simen et al., 2011) and increased IL-1β in aged 
individuals is associated with risk of neurodegenerative diseases such as Alzheimer’s (W.-Y. 
Wang, Tan, Yu, & Tan, 2015). 
 Notwithstanding, it is proposed that certain nutrients can manipulate the epigenome to 
delay brain aging by preventing or reversing microglial aging, potentially through DNA 
methylation, histone modifications, and their interactions (Hoeijmakers, Heinen, van Dam, 
Lucassen, & Korosi, 2016). Butyrate, a short-chain fatty acid (SCFA) produced by bacterial 
fermentation of fiber in the colon, has been extensively studied for its beneficial effects through 
free fatty acid receptor signaling and metabolic regulation, but also pharmacologically as a 
histone deacetylase (HDAC) inhibitor. HDAC inhibitors have become an attractive therapeutic 
candidate due to the ability to increase histone acetylation and promote the expression of 
neurotrophic and anti-inflammatory genes (Huuskonen et al., 2004; Patnala et al., 2016). 
Although most studies using butyrate have focused on its effects on histone acetylation, there is 
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also evidence that butyrate can affect DNA methylation (Sarkar et al., 2011; Shin, Kim, Lee, & 
Lee, 2012; Wei, Melas, Wegener, Mathé, & Lavebratt, 2015). 
Sodium butyrate (NaB), the sodium salt form of butyrate, is most commonly used in 
pharmacological studies and has been shown to decrease pro-inflammatory cytokines of 
microglia in vitro as well as improve learning and memory in mouse models of 
neurodegenerative diseases when injected intraperitoneally (i.p.) (Govindarajan et al., 2011; 
Kilgore et al., 2010).  It has even recently been demonstrated that NaB triggers elongation of 
microglial processes and can abolish LPS-induced depressive like behaviors through decreasing 
microglial activation (P. Wang et al., 2018; Yamawaki et al., 2018). 
To date, only a handful of studies have probed the mechanistic basis surrounding the 
beneficial neurological effects of a high fermentable fiber, which has the capacity to shift SCFA 
production to favor butyrate (Bourassa et al., 2016). Notably, one study found significant 
immune benefits in the brain of mice fed a high fermentable (soluble) fiber diet and found that 
they recovered faster from LPS-induced sickness (Sherry et al., 2010). After exposure to LPS, 
mice fed the soluble fiber diet showed an increase in IL-1RA and a decrease in IL-1β and TNF-α 
in the brain. Brain IL-4 mRNA was also increased, and as IL-4 expression is enhanced by 
increased histone acetylation, the authors hypothesized that the elevated butyrate from the 
dietary fiber fermentation may contribute to the immune response. It is still not fully understood 
however, if an increase in butyrate-producing bacteria in the gut as a consequence of soluble 
fiber diet, could affect microglial activation, and specifically microglial activation in aging. 
SCFA concentrations are likely less than optimal in older adults, as data indicates daily 
dietary fiber intake for both older men and women is roughly 40% below the recommended 
adequate intake (King, Mainous, & Lambourne, 2012). There is also a lower capacity to produce 
65 
 
butyrate in the elderly gut microbiome, as suggested by the findings that there are significantly 
fewer copies of the butyrilCoA:acetateCoA transferase gene compared to younger adults and 
lower amounts of bacterial groups which are known butyrate producers (Biagi et al., 2011; Hippe 
et al., 2011). Therefore, the aging population is an important demographic for where increased 
fiber supplementation is needed. Of note, inulin has been shown to be a rich source of soluble 
dietary fiber that increases butyrate-producing bacteria (G. Schaafsma & Slavin, 2015).  Inulin 
belongs to a group of non-digestible carbohydrates called fructans, and in food is considered a 
prebiotic (Roberfroid, 2007). Studies have specifically demonstrated that inulin is beneficial for 
age-related inflammation, as a nutritional supplement with inulin increased innate immunity and 
protection against infections in elderly people (Bunout et al., 2004). Thus, an increase in butyrate 
through added soluble fiber such as inulin could counterbalance the age-related microbiota 
dysbiosis, and potentially lead to neurological benefits. 
We first wanted to determine if NaB pharmacologically has beneficial effects on 
microglia in aged mice with and without an immune challenge. With this being the case, we then 
hypothesized that butyrate derived from soluble fiber (inulin) in aged mice would promote 
changes in the microbiome and decreases in peripheral inflammation leading to decreased 
neuroinflammation. Last, we hypothesized that a high soluble fiber diet could diminish or even 









Experiment 1: Effects of intraperitoneal administration of sodium butyrate in adult and 
aged mice in both microglia and hippocampus in response to LPS 
Animals  
Adult (3-6-month-old) and aged (22-25 month-old) Balb/c male mice were reared in-
house and provided with ad libitum access to chow (Teklad 8640, Harlan laboratories, 
Indianapolis, IN, USA) and water. Mice were individually housed in a temperature-controlled 
environment with a 12-hour reversed-phase light/dark cycle (lights on 21:00h).  
Treatments were designed in a 2 x 2 factorial arrangement and administered at the onset of the 
dark cycle. Both Escherichia coli LPS (serotype 0127:B8, Sigma, St. Louis, MO, USA) and NaB 
(Sigma, St. Louis, MO, USA) were dissolved in sterile saline before experimentation. Mice from 
both age groups were injected i.p. with either saline (control) or NaB at 1.2g/kg body weight and 
2 hours later with saline or LPS at 0.33 mg/kg body weight. This dose of NaB was selected based 
on previous studies demonstrating significant beneficial effects in other rodent models (Blank et 
al., 2015; Dash, Orsi, & Moore, 2009; Govindarajan et al., 2011). This dose of LPS was selected 
based on previous studies demonstrating that 0.33 mg/kg LPS produced prolonged sickness 
behavior in aged compared with young mice (Godbout et al., 2005). Treatments were 
administered at 9 AM for all cohorts. Body weight was measured at baseline and 4 hours after 
injections as an index of sickness response. 
Tissue Collection and Microglia Isolation 
Animals were euthanized via CO2 asphyxiation and animals were perfused with sterile 
ice-cold saline. Brain tissue (all but the hippocampus which was frozen in dry ice) was collected 
and used immediately for microglia isolation using a procedure adapted from Nikademova & 
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Watters (Maria Nikodemova & Watters, 2012). Brains were enzymatically digested using the 
Neural Tissue Dissociation Kit (Miltenyi Biotec, Germany) for 35 min at 37° C. Further 
processing was performed at 4° C. Tissue debris was removed by passing the cell suspension 
through a 40 µm cell strainer. After myelin removal using 30% Percoll Plus (GE Healthcare, 
Princeton, NJ, USA), cells in PBS supplemented with 0.5% BSA and 2 mM EDTA were 
incubated for 15 minutes with anti-Cd11b magnetic beads (Miltenyi Biotec, Germany). CD11b+ 
cells were extensively washed and separated in a magnetic field using MS columns (Miltenyi 
Biotec, Germany) before being directly placed in Trizol reagent (Invitrogen). 
RNA isolation and real-time RT-PCR 
Total RNA from microglia and hippocampus was isolated using the Tri Reagent protocol 
(Invitrogen). Synthesis of cDNA was carried out using a high-capacity RT kit (Applied 
Biosystems, Grand Island, NY, USA) according to the manufacturer’s instructions. Real-time 
RT-PCR was performed on an ABI PRISM 7900HT-sequence detection system (Perkin Elmer, 
Forest City, CA, USA). All genes were analyzed using PrimeTime real-time RT-PCR Assays 
(Integrated DNA Technologies, Coralville, IA, USA) and were compared with the housekeeping 
control gene GAPDH (Mm99999915_g1) using the 2−ΔΔCt calculation method as previously 
described (Livak & Schmittgen, 2001). Data are expressed as fold change versus saline control 
adult mice.  
Fluidigm 
Total RNA from microglia was isolated using the Tri Reagent protocol (Invitrogen) and 
synthesis of cDNA was carried out using a high-capacity RT kit (Applied Biosystems) as 
previously described for real-time RT-PCR. Fluidigm reactions were performed by the UIUC 
Functional Genomics Unit of the W.M. Keck Center using a 96 × 96 chip and included 2 
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technical replicates for each combination of sample and assay. Data was acquired using the 
Fluidigm Real-Time PCR Analysis software 3.0.2 (Fluidigm, San Francisco, CA, USA). Data 
from Fluidigm runs were manually checked for reaction quality before analysis, and Ct values for 
each gene target (see Table 4.1) were normalized to Ct values for the housekeeping gene Gapdh.  
Experiment 2: Effects of low and high soluble fiber diets on central and peripheral 
inflammation in adult and aged mice  
Animals and Diet 
Adult (3-6-month-old) and aged (22-25 month-old) male Balb/c mice were housed as 
described in Experiment 1, but were fed either AIN-93M diet with 5% cellulose (product # 
D10012M, Research Diets, Inc., New Brunswick, NJ, USA) or one of two AIN-93M modified 
diets that contained either 1% cellulose (product # D16060605, Research Diets, Inc., New 
Brunswick, NJ, USA) or 1% cellulose and 5% inulin (product # D16060606, Research Diets, 
Inc., New Brunswick, NJ, USA) for four weeks. Composition of these diets can be seen in Table 
4.2, modified from Research Diets, Inc. Fecal samples were taken from the mice (on chow) prior 
to the start of the study in order to assess baseline microbiome changes between adult and aged. 
Body weight was measured immediately prior to euthanasia to assess any weight differences 
with the diets. All studies were carried out in accordance with United States National Institutes 
of Health guidelines and approved by the University of Illinois Institutional Animal Care and 
Use Committee. 
Tissue Collection and Microglia Isolation  
Animals were euthanized via CO2 asphyxiation, blood was taken, and animals were 
perfused with sterile ice-cold saline. Samples were collected from colon, liver, mesenteric lymph 
nodes, and hippocampus that were frozen on dry ice. Cecal content and feces were also taken for 
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analysis of SFCA concentrations and microbiota compositions, respectively. Distal colon was 
taken for histological analysis. Brain tissue (all but the hippocampus) was collected and used 
immediately for microglia isolation as described in Experiment 1.  
Bacterial DNA isolation and 16S rRNA sequencing 
Fecal bacterial DNA was extracted using the PowerLyzer PowerSoil DNA Isolation Kit 
(MOBIO Laboratories, Inc.) and quality was assessed via gel electrophoresis. The DNA library 
was constructed using a Fluidigm Access Array system in the Functional Genomics Unit of the 
Roy J. Carver Biotechnology Center at the University of Illinois at Urbana (UIUC). After library 
construction, a 250 bp region of the 16S rRNA gene (V4) were amplified using a PCR 
amplification method modified from Muturi et al. (Muturi, Donthu, Fields, Moise, & Kim, 
2017).  Briefly, DNA samples were diluted to 2 ng/µl and amplified with Roche High Fidelity 
Fast Start Kit and 20x Access Array loading reagent prior to PCR. Samples were amplified using 
the following Access Array cycling program 50 °C for 2 minutes (1 cycle), 70 °C for 20 minutes 
(1 cycle), 95 °C for 10 minutes (1 cycle), followed by 10 cycles at 95 °C for 15 seconds, 60 °C 
for 30 seconds, and 72 °C for 1minute, 2 cycles at 95 °C for 15 seconds, 80 °C for 30 seconds, 
60 °C for 30 seconds, and 72 °C for 1 minute, 8 cycles at 95 °C for 15 seconds, 60 °C for 30 
seconds, and 72° for 1minute, 2 cycles at 95 °C for 15 seconds, 80 °C for 30 seconds, 60 °C for 
30 seconds, and 72 °C for 1minute, 8 cycles at 95 °C for 15 seconds, 60 °C for 30 seconds, and 
72 °C for 1minute, and 5 cycles at 95 °C for 15 seconds. After PCR, all samples were run on a 
Fragment Analyzer (Advanced Analytics, Ames, IA). Samples were then pooled in equal 
amounts according to PCR product concentration. The pooled products were then size selected 
on a 2% agarose E-gel (Life Technologies) and extracted from the isolated gel slice with Qiagen 
gel extraction kit (Qiagen).  Cleaned size selected products were run on an Agilent Bioanalyzer 
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to confirm appropriate profile and determination of average size.  The final library pool was 
spiked with 10% non-indexed PhiX control library (Illumina®) and sequenced using Illumina® 
MiSeq® V3 Bulk system. The libraries were sequenced from both ends of the molecules to a 
total read length of 250 nt from each end. High-quality (> 25) sequence data (FASTQ) from the 
forward read were analyzed with QIIME 2.054. Quality control consisted of depleting or 
removing barcodes, primers, and short sequences (< 187 bp), sequences with ambiguous base 
calls, and sequences with homopolymer runs exceeding 6 bp. After removal of singletons, OTUs 
were classified using closed reference picking against Greengenes database at 97% similarity. b-
diversity (weighted and unweighted UniFrac distances) were computed at an even sampling 
depth of 10,048 sequences per sample based on α-diversity (Chao1) rarefaction plots 
(Supplementary Figure 4.3) 
Short chain fatty acid analysis 
SCFAs were analyzed by dry matter content as described previously by Panasevich et al 
(Panasevich, Allen, Wallig, Woods, & Dilger, 2015). To calculator dry matter percentage, a 
portion (~0.08-0.15 grams) of wet cecal contents were weighed and then heated in oven for 24 
hours to dry samples. Resulting dry matter percentage was calculated as [weight of dry 
sample/weight (g) of wet sample (g) *100]. The rest of the cecal contents (~0.05-0.15 grams) 
were acidified immediately after collection in 6.25% meta-phosphoric acid solution and stored at 
−20°C until analysis. After thawing, samples were spun down at 10,000 rpm for 8 minutes and 
supernatant was collected for analysis. SCFA concentrations (wet) were determined by gas 
chromatography by using a gas chromatograph (Hewlett-Packard 5890A Series II) and a glass 
column (180 cm × 4 mm i.d.), packed with 10% SP-1200/1% H3PO4 on 80/100 + mesh 
Chromosorb WAW (Supelco, Inc.). Nitrogen was the carrier gas with a flow rate of 75 mL/min. 
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Oven, detector, and injector temperatures were 125°, 175°, and 180°C, respectively. Acetic, n-
butyric, and propionic acid solutions (Sigma-Aldrich) were used as standards.  
RNA isolation and real-time RT-PCR  
Total RNA from microglia, hippocampus, colon, liver, and mesenteric lymph nodes was 
isolated and synthesis of cDNA was carried out as described in Experiment 1. Real-time RT-
PCR was performed also as described in Experiment 1 with the exception that data are expressed 
as fold change versus control adult mice on AIN-93M diet.  
Fluidigm 
As described in Experiment 1.   
DNA Isolation and Pyrosequencing 
Total DNA from microglia and hippocampus tissue was isolated using the Tri Reagent 
protocol (Invitrogen). DNA methylation for 2 CpG sites within the proximal promoter region of 
Il1b was assessed via bisulfite pyrosequencing on bisulfite modified DNA (Zymo Research, 
Irvine, CA, USA). The mouse Il1b methylation assay (ID ADS3713-RS1 was purchased from 
EpigenDx (Hopkinton, MA, USA) and has been previously used to assess methylation status in 
microglia (Cho et al., 2015). PCRs were run in duplicate and contained 20 ng of bisulfite 
converted DNA as starting template. Product specificity was determined by gel electrophoresis. 
The primer was also tested using bisulfite converted DNA from high and low methylation 
controls (EpigenDx, Hopkinton, MA, USA). Qiagen's PyroMark Q24 Advanced Pyrosequencer 
was used to detect DNA methylation levels following manufacturer's protocols and default 





Distal Colon Histology 
Distal colon was fixed in Methacarn (60% methanol, 30% chloroform, 10% acetic acid) 
for 72 hours and then placed in 100% ethanol until tissue embedding. Distal colon tissue was 
paraffin embedded, and 5µm sections mounted on glass slides were stained with hematoxylin 
and eosin (H&E) for assessment of intestinal morphology. Histology was scored by a trained, 
blinded observer on a modified version of a published scoring (Erben et al., 2014) system that 
considers four criteria: inflammatory cell infiltration (0-4), goblet cell mucus depletion (0-4); 
destruction of architecture (0-4) and crypt abscesses (0-4). Overall histology score was 
quantified using an aggregate of these scores. 
LPS Binding Protein (LBP) Assay 
LBP was quantified in serum samples using the Mouse LBP enzyme-linked 
immunosorbent assay (ELISA) Kit (catalog #: HK205-02, Hycult Biotech Inc., Plymouth 
Meeting, PA, USA). The assay was run according to the manufacturer’s instructions. 
Experiment 3: Effects of low and high soluble fiber diets on central and peripheral 
inflammation in adult and aged mice stimulated with LPS 
Animals and Diet 
Adult (3-6-month-old) and aged (22-25 month-old) male Balb/c mice were housed and 
fed diets as described in Experiment 2. Mice were injected i.p. with LPS at 0.33 mg/kg body 
weight as described in Experiment 1. Body weight was measured at baseline and 4 hours after 
injections as an index of sickness response. All studies were carried out in accordance with 
United States National Institutes of Health guidelines and approved by the University of Illinois 




Tissue Collection and Microglia Isolation 
Animals were euthanized via CO2 asphyxiation, blood was taken, and animals were 
perfused with sterile ice-cold saline. Samples were collected from colon, liver, mesenteric lymph 
nodes, and hippocampus that were frozen on dry ice. Brain tissue (all but the hippocampus) was 
collected and used immediately for microglia isolation as described in Experiment 1 and 2.  
RNA isolation and real-time RT-PCR 
Isolation of RNA, cDNA synthesis, and Real-time RT-PCR were performed as described 
in Experiment 2.  
DNA Isolation and Pyrosequencing 
As described in Experiment 2.  
LPS Binding Protein (LBP) Assay  
As described in Experiment 2. 
Statistical Analyses 
Body weight, gene expression (including Fluidigm), SCFA analysis, pyrosequencing, 
colon histology scoring, and LBP data were analyzed using Statistical Analysis System (SAS, 
Cary, NC, USA) and were subjected to 2-way analysis of and all interactions. Where analysis of 
variance revealed a significant interaction (p < 0.05), Fisher’s LSD test was used for post hoc 
comparisons when appropriate. Microbiome community compositions (β- diversity; weighted 
Unifrac) were compared across ages and diets with permutational analysis of variance analysis 
(PERMANOVA). Next, to unbiasedly identify key features of the gut microbiota that are 
affected by age and fiber diets, Random Forest (RF) alongside Boruta feature selection was 
performed Boruta selection uses RF to iteratively compare importance of independent variables 
with that of pseudo-random (shadow) attributes (Kursa, 2014). Variables ‘confirmed’ by Boruta 
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feature selection had significantly higher RF importance scores than ‘shadow’ attributes and 
could therefore delineate between diet and age. Analysis was performed on R random forest 
package with 1000 trees and all other default values. All data are expressed as means ± SEM.  
Table 4.1. Primers used in Real-time RT-PCR and Fluidigm experiments. 


























































Table 4.1 (cont.). Primers used in Real-time RT-PCR and Fluidigm experiments. 
Table 4.2. AIN-93M Mature Rodent Diet and Modified AIN-93M Diets with 10 gm Cellulose or 10 gm 
Cellulose + 50 gm Inulin per 3850 kcal.  
 
Product #  D10012M  D16060605  D16060606  
 AIN-93M  
10 gm 
Cellulose/3850kcal  
10 gm cellulose + 50 gm 
Inulin/3850kcal  
 gm%  kcal%  gm%  kcal%  gm%  kcal%  
Protein  14  15  15  15  14  15  
Carbohydrate  73  76  76  76  72  74  
Fat  4  9  4  9  4  9  
Total   100   100   98  
kcal/gm  3.85   4.01   3.88   
       
Ingredient  gm  kcal  gm  kcal  gm  kcal  
Casein  140  560  140  560  140  560  
L-Cystine  1.8  7  1.8  7  1.8  7  
Corn Starch  495.692  1983  495.692  1983  476.942  1908  
Maltodextrin 10  125  500  125  500  125  500  
Sucrose  100  400  100  400  100  400  
Cellulose, BW200  50  0  10  0  10  0  
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Product #  D10012M  D16060605  D16060606  
Inulin  0  0  0  0  50  75  
Soybean Oil  40  360  40  360  40  360  
t-Butylhydroquinone  0.008  0  0.008  0  0.008  0  
Mineral Mix 
S10022M  
35  0  35  0  35  0  
Vitamin Mix V10037  10  40  10  40  10  40  
Choline Bitartrate  2.5  0  2.5  0  2.5  0  
FD&C Yellow Dye 
#5  
0  0  
0 0.05 0  
0  
0 0.025 0.025  
0  
FD&C Red Dye #40  0  0  0  0  
FD&C Blue Dye #1  0  0  0  0  
       
Total  1000  3850  960.05  3850  991.3  3850  
Cellulose (gm/kg 
diet)  
50.0   10.4   10.1   
Inulin (gm/kg diet)  0.0   0.0   50.4   
 
Table 4.2 (cont). AIN-93M Mature Rodent Diet and Modified AIN-93M Diets with 10 gm Cellulose or 
10 gm Cellulose + 50 gm Inulin per 3850 kcal.  
 
4.4 Results 
Sodium butyrate downregulates Il1b gene expression in response to LPS in adult and aged 
microglia and hippocampus 
Mice were either pre-treated i.p. with saline (SAL) or NaB, and then given an i.p. 
injection of either SAL or LPS two hours later. For body weight, LPS-treated adult and aged 
mice lost more weight (main effect of LPS, p=0.0052 and p<0.0001) as expected, but there was 
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also an interaction (NaB x LPS, p=0.0391) with the aged mice in that NaB pre-treated mice with 
LPS did not lose as much weight as the SAL pre-treated mice with LPS (data not shown).  
Fluidigm gene expression analysis on microglia was performed to gain a more 
comprehensive assessment of microglial gene regulation in response to NaB (Table 4.3 and 
Table 4.4). However, there were very few changes associated with NaB in the majority of genes 
analyzed, so we chose to focus on pro-inflammatory cytokine gene expression (Figure 4.1A-C). 
In adult microglia, for Il1b, there were main effects of LPS (p=0.0005), NaB (p=0.0447), and a 
trending interaction (p=0.0774) in that NaB decreased LPS-induced Il1b expression. In aged 
microglia, for Il1b, there were main effects of LPS (p<0.0001), NaB (p=0.0497), and an 
interaction (p=0.0178) in that NaB decreased LPS-induced Il1b expression. For microglial Tnf, 
there were only main effects of LPS in both adult and aged mice (p=0.02 and p=0.003). For 
microglial Il-6, there was only a main effect of LPS in aged mice (p<0.0001). 
Similar changes were also observed in the hippocampus (Figure 4.1D-F). In the adult 
hippocampus, for Il1b, there was only a main effect of LPS (p=0.0018). But in the aged 
hippocampus, for Il1b, there were main effects of LPS (p<0.0001), NaB (p=0.0246), and an 
interaction (p=0.0257) in that NaB decreased LPS-induced Il1b expression. For hippocampal Tnf 
and Il-6, there were only main effects of LPS in both adult and aged mice (p=0.0031 and 




Figure 4.1. Microglial and hippocampal gene expression 4 hours after SAL/LPS i.p. injections in adult 
and aged mice pre-treated with i.p. SAL/NaB. Data are presented as means ± SEM (n=7-10) for 
microglial (A) Il1b, (B) Tnf, (C) Il-6 and hippocampal (D) Il1b, (E) Tnf, and (F) Il-6 gene expression. 
Treatment means with different letters are significantly different. * indicates a main effect with 













Table 4.3. Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in microglia 
collected at 4 hours after SAL/LPS i.p. injections in adult mice pre-treated with i.p. SAL/NaB. Data are 
presented as means ± SEM (n=7-10) and p-values for main effects of NaB and LPS as well as NaB x LPS 
interactions are also included. 
 
A. Inflammatory and Regulators of Inflammatory Genes 
 p-values 
Gene SAL + SAL NaB + SAL SAL + LPS NaB + LPS NaB LPS NaB x LPS 
Arg1 1.21±0.31 1.21±0.61 2.09±0.39 0.94±0.24 0.161 0.454 0.165 
Casp1 0.95±0.19 1.21±0.25 0.77±0.14 0.52±0.10 0.98 0.029* 0.193 
Cd68 0.91±0.13 1.08±0.20 0.56±0.08 0.37±0.04 0.929 0.0003* 0.188 
Cx3cr1 0.97±0.17 0.97±0.13 0.41±0.06 0.23±0.02 0.378 <0.0001* 0.373 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
HIF-1a 0.88±0.02 1.18±0.25 1.52±0.41 0.93±0.23 0.720 0.624 0.262 
Igf1 1.06±0.31 1.32±0.25 0.37±0.12 0.21±0.03 0.809 <0.0001* 0.269 
Il-1β 1.22±0.65 1.13±0.18 3.29±0.37 1.83±0.21 0.045* 0.0005* 0.077 
Il-1rn 0.99±0.35 0.81±0.11 19.03±3.82 14.91±3.25 0.436 <0.0001* 0.474 
Il-10 1.10±0.35 0.80±0.16 5.19±0.77 2.21±0.56 0.004* <0.0001* 0.017* 
Il-6 1.23±0.59 0.86±0.12 1.32±0.25 1.01±0.20 0.277 0.709 0.934 
Niarc1 1.16±0.55 1.09±0.20 6.67±1.52 5.41±1.09 0.529 <0.0001* 0.578 
Nlrp3 0.84±0.07 1.59±0.52 1.05±0.25 0.80±0.21 0.548 0.484 0.234 
Pycard 0.99±0.06 0.75±0.02 0.61±0.07 0.68±0.03 0.097 <0.0001* 0.004* 
Socs1 1.01±0.25 1.74±0.28 1.39±0.17 1.40±0.26 0.143 0.947 0.148 
Socs3 0.98±0.23 1.82±0.55 3.86±0.95 3.20±0.72 0.914 0.011* 0.361 
Stat3 0.87±0.06 0.92±0.11 2.69±0.32 2.10±0.28 0.345 <0.0001* 0.264 
Tlr2 0.94±0.15 1.13±0.18 1.78±0.38 1.71±0.41 0.877 0.062 0.730 
Tlr4 1.02±0.14 1.01±0.16 0.47±0.06 0.36±0.04 0.599 <0.0001* 0.656 
Tlr7 0.86±0.04 0.92±0.13 1.32±0.16 1.00±0.12 0.444 0.128 0.275 
Tlr8 0.94±0.18 1.01±0.17 1.35±0.21 0.89±0.12 0.323 0.447 0.177 
Tnf 0.97±0.14 1.01±0.20 1.84±0.31 1.35±0.23 0.371 0.02* 0.306 
 
B. Sensome Genes 
     p-values 
Gene SAL + SAL NaB + SAL SAL + LPS NaB + LPS NaB LPS NaB x LPS 
Cd53 0.92±0.09 0.96±0.13 0.93±0.12 0.71±0.08 0.475 0.340 0.300 
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Gpr34 0.96±0.12 1.14±0.22 0.20±0.05 0.08±0.02 0.822 <0.0001* 0.338 
P2ry12 1.18±0.49 0.88±0.09 0.31±0.06 0.17±0.02 0.312 0.0004* 0.69 
P2ry13 0.93±0.12 0.90±0.12 0.43±0.05 0.28±0.02 0.299 <0.0001* 0.509 
Siglech 0.94±0.13 1.07±0.18 0.53±0.08 0.32±0.04 0.781 <0.0001* 0.192 
Tgfbr1 0.93±0.18 1.19±0.24 0.53±0.08 0.34±0.04 0.842 0.0003* 0.170 
Tmem119 1.09±0.27 2.04±0.62 0.55±0.11 0.32±0.05 0.362 0.005* 0.133 
Trem2 0.93±0.31 2.16±0.61 0.86±0.19 0.62±0.14 0.192 0.035* 0.053 
 
C. Epigenetic Regulator Genes 
     p-values 
Gene SAL + SAL NaB + SAL SAL + LPS NaB + LPS NaB LPS NaB x LPS 
Hdac2 0.97±0.21 1.27±0.25 0.99±0.18 0.71±0.13 0.958 0.226 0.195 
Hdac3 0.91±0.13 1.00±0.16 0.76±0.10 0.58±0.08 0.725 0.031* 0.305 
Hdac4 0.93±0.29 1.61±0.32 3.67±0.92 3.16±0.73 0.902 0.004* 0.404 
Hdac5 0.99±0.26 1.82±0.41 0.54±0.12 0.32±0.05 0.247 0.0004* 0.0457* 
Hdac6 0.97±0.27 1.76±0.38 1.87±0.40 1.19±0.24 0.883 0.673 0.059 
Tet1 0.94±0.07 1.00±0.16 0.29±0.07 0.12±0.02 0.621 <0.0001* 0.313 
Tet2 1.03±0.18 1.23±0.23 1.32±0.29 1.23±0.25 0.855 0.633 0.641 
Tet3 1.03±0.27 2.42±0.69 0.81±0.19 0.57±0.14 0.167 0.013* 0.049* 
 
Table 4.3 (cont.). Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in 
microglia collected at 4 hours after SAL/LPS i.p. injections in adult mice pre-treated with i.p. SAL/NaB. 
Data are presented as means ± SEM (n=7-10) and p-values for main effects of NaB and LPS as well as 




Table 4.4. Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in microglia 
collected at 4 hours after SAL/LPS i.p. injections in aged mice pre-treated with i.p. SAL/NaB. Data are 
presented as means ± SEM (n=7-10) and p-values for main effects of NaB and LPS as well as NaB x LPS 
interactions are also included. 
 
A. Inflammatory and Regulators of Inflammatory Genes 
 p-values 
Gene SAL + SAL NaB + SAL SAL + LPS NaB + LPS NaB LPS NaB x LPS 
Arg1 2.82±1.46 1.38±0.55 5.65±1.37 4.69±0.75 0.252 0.005* 0.812 
Casp1 0.62±0.13 0.73±0.13 0.45±0.10 0.49±0.07 0.482 0.053 0.790 
Cd68 0.74±0.15 0.93±0.16 0.47±0.09 0.44±0.05 0.508 0.0016* 0.364 
Cx3cr1 0.51±0.09 0.58±0.07 0.18±0.02 0.18±0.02 0.582 <0.0001* 0.576 
HIF-1a 0.76±0.17 0.95±0.19 2.14±0.57 2.09±0.40 0.850 0.0013* 0.744 
Igf1 1.15±0.33 1.55±0.33 0.26±0.07 0.24±0.04 0.360 <0.0001* 0.304 
Il-1β 1.77±0.40 1.93±0.31 5.24±0.52 3.54±0.30 0.050* <0.0001* 0.018* 
Il-1rn 2.81±0.50 3.07±0.36 38.12±3.75 27.25±2.91 0.036* <0.0001* 0.028* 
Il-10 1.42±0.39 2.23±0.59 12.67±3.90 7.28±1.44 0.239 <0.0001* 0.113 
Il-6 0.70±0.12 0.81±0.12 2.32±0.39 1.96±0.33 0.659 <0.0001* 0.398 
Niarc1 1.34±0.26 1.52±0.27 7.38±1.53 8.21±1.43 0.656 <0.0001* 0.771 
Nlrp3 1.02±0.34 1.14±0.29 1.26±0.45 1.16±0.24 0.964 0.699 0.744 
Pycard 0.99±0.06 0.75±0.02 0.61±0.07 0.68±0.03 0.097 <0.0001* 0.004* 
Socs1 1.71±0.18 2.05±0.19 1.69±0.31 1.41±0.25 0.899 0.176 0.205 
Socs3 1.16±0.30 1.21±0.22 5.53±1.57 4.21±0.85 0.488 0.0001* 0.460 
Stat3 0.59±0.08 0.55±0.06 2.36±0.32 1.98±0.22 0.306 <0.0001* 0.411 
Tlr2 0.90±0.16 1.09±0.16 3.05±0.66 2.41±0.35 0.566 <0.0001* 0.294 
Tlr4 0.62±0.12 0.66±0.10 0.41±0.06 0.33±0.03 0.816 0.0014* 0.510 
Tlr7 0.55±0.08 0.54±0.07 0.96±0.14 0.88±0.08 0.657 0.0002* 0.700 
Tlr8 1.34±0.27 1.41±0.28 2.30±0.51 1.89±0.26 0.612 0.035* 0.486 
Tnf 1.23±0.26 1.62±0.28 3.13±0.74 2.49±0.37 0.783 0.003* 0.257 
 
 
B. Sensome Genes 
     p-values 
Gene SAL + SAL NaB + SAL SAL + LPS NaB + LPS NaB LPS NaB x LPS 
Cd53 0.54±0.10 0.55±0.08 0.64±0.08 0.74±0.007 0.487 0.093 0.571 
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Gpr34 0.54±0.01 0.60±0.11 0.05±0.01 0.06±0.01 0.681 <0.0001* 0.727 
P2ry12 0.48±0.07 0.52±0.07 0.12±0.01 0.11±0.01 0.706 0.0004* 0.629 
P2ry13 0.48±0.09 0.50±0.06 0.25±0.04 0.24±0.02 0.938 <0.0001* 0.849 
Siglech 0.56±0.12 0.55±0.09 0.28±0.05 0.28±0.04 0.946 0.0006* 0.957 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Tgfbr1 0.61±0.13 0.73±0.13 0.27±0.06 0.31±0.04 0.439 0.0002* 0.679 
Tmem119 1.06±0.35 1.36±0.40 0.27±0.09 0.31±0.08 0.506 0.0006* 0.613 
Trem2 1.52±0.48 2.07±0.49 0.68±0.24 0.68±0.14 0.449 0.0025* 0.439 
 
 
C. Epigenetic Regulator Genes 
     p-values 
Gene SAL + SAL NaB + SAL SAL + LPS NaB + LPS NaB LPS NaB x LPS 
Hdac2 0.78±0.17 0.84±0.16 0.61±0.11 0.62±0.07 0.802 0.138 0.842 
Hdac3 0.59±0.11 0.65±0.10 0.53±0.08 0.52±0.06 0.750 0.278 0.677 
Hdac4 1.09±0.26 1.11±0.22 2.32±0.52 3.00±0.57 0.432 0.0008* 0.452 
Hdac5 1.14±0.32 1.67±0.33 0.28±0.07 0.27±0.05 0.257 <0.0001* 0.247 
Hdac6 0.83±0.22 1.06±0.21 1.43±0.37 1.20±0.21 0.997 0.149 0.360 
Tet1 0.48±0.08 0.51±0.07 0.07±0.01 0.07±0.01 0.747 <0.0001* 0.808 
Tet2 0.86±0.18 0.89±0.16 1.34±0.28 1.40±0.27 0.843 0.040* 0.962 
Tet3 1.16±0.35 1.65±0.43 0.71±0.20 0.65±0.09 0.466 0.014* 0.348 
 
Table 4.4 (cont.). Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in 
microglia collected at 4 hours after SAL/LPS i.p. injections in aged mice pre-treated with i.p. SAL/NaB. 
Data are presented as means ± SEM (n=7-10) and p-values for main effects of NaB and LPS as well as 
NaB x LPS interactions are also included. 
 
Significant shifts in the microbiome associated with age  
At baseline, β-diversity analysis revealed that gut microbiota composition was different between 
adult (3-6 months) and aged (22-25 months) mice fed a normal chow diet (PERMANOVA 
p<0.05). Random forest analysis with Boruta feature selection identified lower levels of 
Mucuspirillum spp. and Odoribacter spp., and higher levels of in Ruminococcus spp., 




Figure 4.2. Random forest analysis with Boruta feature identifies eight bacterial genera within the fecal 
microbiome that discriminate between adult and aged mice fed a normal chow diet. Scale bar represents 





Figure 4.3. α-diversity rarefaction plots as determined by Chao1. No differences in α- diversity were 
observed as a result of age (blue: adult mice red: aged mice; shown above) or fiber feeding (data not 
shown).  
 
High soluble fiber diet alters microbiota and increases production of SCFA’s 
Adult and aged mice were fed either a low fiber (1% cellulose) or high fiber (1% cellulose 
+ 5% inulin) diet for 4 weeks. For body weight, there were no differences in body weight for age 
or diet (p>0.05, data not shown).  
β-diversity analysis revealed a robust effect of 4 weeks of soluble fiber feeding on gut 
microbiota composition (PERMANOVA p<0.05; Supplementary Figure 4.4).  Of note, inulin 
feeing led to lower abundances of Ruminococcus spp. and f. Rikenellaceae, two taxa that were 
more highly represented in aged mice fed a chow diet. Cecal contents were analyzed for SCFA 
concentrations to assess the magnitude and profile of fermentation end products (Figure 4.5). 
Inulin feeding led to an increase in cecal acetate (p=0.0066) and butyrate (p=0.009), and total 
SCFAs (p=0.0107), irrespective of age. Propionate concentrations were not responsive to diet nor 







Figure 4.4. β-diversity analysis (weighted Unifrac) reveals differences in gut microbiota community 
composition between high fiber-fed (green) and low fiber-fed (orange) mice after 4 weeks of feeding.  
 
 
Figure 4.5. Cecal content concentrations of (A) butyrate, (B) acetate, (C) propionate, and (D) total 
SCFAs in adult and aged mice fed a LF (1% cellulose) or HF (1% cellulose and 5% inulin) diet. Data are 
presented as means ± SEM (n=6-8). * indicates a main effect with significance at p<0.05. 
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Fiber alters expression of inflammatory, sensome, and epigenetic regulator genes in adult 
and aged microglia and butyrate correlates positively with reduced microglial 
inflammatory gene expression 
Fluidigm gene expression analysis on microglia was performed to gain a more 
comprehensive assessment of microglial gene regulation in response to diets with low and high 
fiber (Figure 4.6A). For inflammatory and regulators of inflammatory genes, there were a number 
of significant main effects of diet in that high fiber decreased gene expression (Il1b, Il-1rn, Il-6, 
Nlrp3, Tlr4, Tnf) (Table 4.5A). For sensome genes, there were main effects of diet for all genes 
analyzed (see Table 4.5B), as well as an interaction with Trem2 in which aged mice on the low 
fiber diet had the highest expression but decreased to levels similar to the adult groups with the 
high fiber diet. For epigenetic regulator genes, there were also main effects of almost all genes 
analyzed, in that high fiber decreased expression (Table 4.5C). Of note, some epigenetic regulator 
genes were affected by age similar to what has been demonstrated previously (Hdac1, Gadd45b) 
(Matt et al., 2016).  
We also wanted to determine if the increased butyrate seen with the high fiber diet is related 
to the anti-inflammatory effect seen in the brain. Correlating microglial Il1b, Il-6, and Tnf with 
concentrations of butyrate demonstrated that for Il1b and Tnf (trend for Il-6), higher butyrate 
correlated with lower pro-inflammatory gene expression (Figure 4.6B-D). 
Fiber does not alter expression of inflammatory genes or Il1b DNA methylation in adult and 
aged hippocampus 
Only main effects of age were observed in the hippocampus of adult and aged mice fed low and 
high fiber diets (Il1b, p=0.0074, Tnf, p=0.0145, and Il-6, p>0.05) (Figure 4.6E-G). Due to low 
DNA yield, we were not able to assess Il1b DNA methylation in microglia. However, in the 
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hippocampus (Figure 4.6H-I), analysis of Il1b DNA methylation revealed a main effect of age 






Figure 4.6. (A) Heat map visualization of relative expression of genes in microglia analyzed by Fluidigm. 
Microglia were collected from adult and aged mice fed a LF (1% cellulose) or HF (1% cellulose and 5% 
inulin) diet. Correlational analyses were performed between cecal concentrations of butyrate and 
microglial (B) Il1b, (C) Tnf, (D) Il-6. Hippocampal (E) Il1b, (F) Tnf, (G) Il-6 gene expression and DNA 
methylation of the Il1b promoter at (H) CpG1 and (I) CpG2. Data are presented as means ± SEM (n=6-
8). * indicates a main effect with significance at p<0.05. 
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Table 4.5. Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in microglia 
collected from adult and aged mice fed low and or high fiber diets. Data are presented as means ± SEM 
(n=7-10) and p-values for main effects of Age and Diet as well as Age x Diet interactions are also 
included. 
 
A. Inflammatory and Regulators of Inflammatory Genes 
 p-values 
Gene Adult LF Adult HF Aged LF Aged HF Age Diet Age x Diet 
Casp1 1.10±0.15 0.68±0.12 1.28±0.15 0.59±0.09 0.734 <0.0001* 0.315 
Cd68 1.80±0.32 1.27±0.22 3.24±0.46 1.42±0.32 0.025* 0.0012* 0.067 
Cx3cr1 1.38±0.22 0.96±0.21 1.46±0.23 0.72±0.17 0.695 0.0079* 0.447 
HIF-1a 1.96±0.35 1.89±0.59 2.74±0.33 0.85±0.15 0.753 0.019* 0.028* 
Ido1 1.37±0.21 0.94±0.27 1.26±0.17 0.76±0.16 0.491 0.0279* 0.872 
Igf1 0.49±0.09 0.68±0.22 1.95±0.30 0.74±0.15 0.0013* 0.0276* 0.0027* 
Il-1β 1.91±0.30 1.30±0.29 6.34±0.68 4.03±0.84 <0.0001* 0.012* 0.134 
Il-1rn 0.48±0.06 0.25±0.07 3.35±3.51 1.26±0.19 <0.0001* 0.0002* 0.0023* 
Il-10 0.70±0.18 2.22±0.64 2.57±0.48 1.07±0.32 0.512 0.989 0.0094* 
Il-6 1.62±0.17 1.08±0.23 1.63±0.17 0.70±0.14 0.327 0.0002* 0.300 
Niarc1 1.44±0.15 1.13±0.08 2.65±0.30 1.46±0.20 0.0002* 0.0004* 0.0293 
Nlrp3 2.24±0.27 1.55±0.39 3.87±0.56 1.57±0.40 0.060 0.001* 0.066 
Pycard 1.58±0.25 0.93±0.19 1.87±0.25 0.91±0.19 0.539 0.0007* 0.506 
Socs1 1.30±0.08 1.29±0.05 0.93±0.11 1.14±0.06 0.0022* 0.246 0.187 
Socs3 1.71±0.30 1.11±0.27 2.27±0.44 1.60±0.51 0.181 0.105 0.918 
Stat3 1.03±0.16 0.72±0.13 1.04±0.13 0.58±0.10 0.617 0.0051* 0.577 
Tlr2 1.21±0.19 0.73±0.14 2.24±0.33 1.04±0.22 0.0048* 0.0006* 0.125 
Tlr4 1.40±0.17 0.85±0.18 1.31±0.17 0.67±0.13 0.419 0.0006* 0.762 
Tlr7 1.35±0.14 1.02±0.24 1.35±0.17 0.65±0.11 0.302 0.0048* 0.293 
Tlr8 2.10±0.46 2.30±0.59 8.72±1.55 2.60±0.52 0.089 0.113 0.013* 
Tnf 2.09±0.29 1.46±0.47 6.42±0.93 3.17±1.03 0.0001* 0.011* 0.081 
 
B. Sensome Genes 
     p-values 
Gene Adult LF Adult HF Aged LF Aged HF Age Diet Age x Diet 
Cd53 2.67±0.59 1.40±0.28 2.53±0.47 1.08±0.21 0.602 0.003* 0.851 
Gpr34 1.46±0.16 0.87±0.22 1.26±0.15 0.54±0.11 0.119 0.0003* 0.698 
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P2ry12 1.05±0.22 1.05±0.22 1.29±0.17 0.60±0.11 0.134 0.005* 0.267 
P2ry13 1.66±0.28 1.26±0.30 1.95±0.31 0.87±0.21 0.876 0.011* 0.231 
Siglech 1.43±0.16 0.81±0.18 1.18±0.14 0.54±0.11 0.089 <0.0001* 0.933 
Tgfbr1 1.84±0.32 1.14±0.22 2.10±0.28 0.81±0.19 0.891 0.0003* 0.262 
Tmem119 2.15±0.38 1.36±0.38 2.36±0.34 0.82±0.25 0.636 0.0014* 0.283 
Trem2 2.80±0.61 1.82±0.33 6.23±1.04 1.99±0.53 0.011* 0.0004* 0.021* 
 
C. Epigenetic Regulator Genes 
     p-values 
Gene Adult LF Adult HF Aged LF Aged HF Age Diet Age x Diet 
Dnmt3a 1.28±0.19 0.83±0.18 1.49±0.18 0.77±0.16 0.681 0.0019* 0.456 
Dnmt3b 2.01±0.31 0.96±0.20 1.41±0.21 0.63±0.12 0.046* 0.0002* 0.566 
Gadd45b 1.01±0.12 0.81±0.22 3.04±0.35 1.60±0.40 <0.0001* 0.006* 0.033* 
Hdac1 1.11±0.02 0.95±0.07 0.83±0.04 0.82±0.03 <0.0001* 0.068 0.106 
Hdac2 1.67±0.30 1.00±0.22 1.87±0.23 0.63±0.14 0.704 0.0001* 0.224 
Hdac3 1.22±0.17 0.94±0.18 1.50±0.20 0.71±0.12 0.855 0.0029* 0.145 
Hdac4 2.20±0.47 1.27±0.33 2.25±0.38 0.93±0.73 0.699 0.0037* 0.595 
Hdac5 2.13±0.38 1.48±0.41 3.18±0.65 2.60±1.04 0.100 0.350 0.957 
Hdac6 1.91±0.27 1.38±0.39 1.86±0.29 0.74±0.17 0.256 0.0085* 0.331 
Mecp2 1.13±0.17 0.77±0.16 1.13±0.17 0.54±0.10 0.429 0.0019* 0.457 
Tet1 1.49±0.17 1.01±0.20 1.09±0.15 0.44±0.09 0.004* 0.001* 0.609 
Tet2 1.75±0.27 1.22±0.23 1.97±0.24 0.64±0.10 0.422 0.0001* 0.080 
Tet3 3.54±0.70 1.90±0.50 5.55±1.09 5.55±2.23 0.021* 0.488 0.489 
 
Table 4.5 (cont). Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in 
microglia collected from adult and aged mice fed low and or high fiber diets. Data are presented as means 
± SEM (n=7-10) and p-values for main effects of Age and Diet as well as Age x Diet interactions are also 
included. 
 
Feeding a diet supplemented with soluble fiber significantly reduces signs of inflammation 
specifically in the aged but does not alter LBP 
Representative images of the cecum and colon from mice fed low fiber and high fiber 
diets reveal increased cecal size with the high fiber diet, indicative of increased fermentation 
(Figure 4.7A). Distal colon samples were stained with H&E to examine morphological changes 
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due to age and fiber diet. Representative pictures (Figure 4.7B-C) indicate severe inflammation 
associated with leukocyte infiltration in aged animals on a low fiber diet. Scoring of histology 
sections for inflammatory infiltrate reveal that there is a main effect of diet (p=0.0499) and an 
interaction (p=0.0499) in that aged mice on the high fiber diet have decreased inflammatory 
infiltrate, with scoring not significantly different from either low fiber or high fiber adult groups 
(Figure 4.7D). With regards to total histological scoring, there is a trending main effect for diet 
(p=0.088) in that diet decreased total score (Figure 4.7E). Lastly, we assessed LBP in serum of 
adult and aged animals fed low and high fiber diets (Figure 4.7F). We found a main effect of age 
(p=0.0298) which matches previous findings from our lab (unpublished results), but no 









































Figure 4.7. (A) Representative images of cecum and colon in mice fed either a low (top) or high (bottom) 
fiber diet. Representative sections of the distal colon of 4-month old (B) and 24-month old (C) mice fed 
either a low (left) or a high (right) diet. Sections were stained with hematoxylin and eosin (H&E). Scale 
bar = 100 µM. Blinded histological scoring of distal colons: (D) inflammatory cell infiltration (score 0-4) 
and (E) total histology score (0-16) (includes aggregate scores of inflammatory cell infiltration (0-4), 
goblet cell mucus depletion (0-4; data not shown), destruction of architecture (0-4; data not shown) and 
crypt abscesses (0-4; data not shown). Data are presented as means ± SEM (n=3). Bars with no SEM 
indicate identical scoring for all mice in the group. Treatment means with different letters are significantly 
different. (F) Serum LBP measured in adult and aged mice fed low or high fiber diets. Data are presented 
as means ± SEM (n=7-10). * indicates a main effect with significance at p<0.05. 
 
Peripheral gene expression does not mirror microglial changes but Tjp2 and FFAR2 
expression are affected by high soluble fiber diet 
Gene expression for the pro-inflammatory cytokines Il1b and Tnf, other inflammatory 
regulators including Il-10 and Il-1rn, Il-17, and Il-23, the histone deacetylase Hdac3, tight 
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junction proteins/intestinal markers Tjp1, Tjp2, Tff3, Ocln, Mct1, and Muc2, as well as the 
FFARs Ffar2 and Gpr109a were measured in colon (Figure 4.8A). There were no significant 
changes in any of the genes analyzed in adult mice (data not shown), so we chose to focus on 
aged animals.  Surprisingly, there were no effects of diet on pro-inflammatory gene expression, 
but there was an effect of diet for Tjp2 (p=0.0396) and Ffar2 (p=0.0319). There were also 
trending effects of diet for Tjp1 (0.0738) and Ocln (p=0.0857). Gene expression for the pro-
inflammatory cytokines Il1b, Tnf, and Il-6 were assessed in lymph nodes and liver, but there 
were no differences between low fiber and high fiber groups in adult (data no shown) or aged 
mice (Figure 4.8B).  
 
Figure 4.8. Gene expression of (A) colon and (B) lymph node and liver samples from aged mice fed either 
a low or high fiber diet. Data are presented as means ± SEM (n=7-10). * indicates significance at p<0.05 
and # indicates significance at p<0.1. 
 
Minimal changes in LPS-treated mice fed low and high fiber diets  
 
For Experiment 3, the treatments were identical to Experiment 2 except that mice were 
injected i.p. with LPS in order to characterize changes in immune stimulus associated with diet. 
For body weight, LPS decreased body weight as expected (1-2 grams on average, data not shown), 
and there were no differences in body weight for age or diet (p>0.05, data not shown).  
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Fluidigm analysis from microglia is shown in Table 4.6. Interestingly, the majority of the 
diet main effects and interactions were seen in the sensome (Cd53, Siglech, P2ry12, P2ry13, 
Trem2, Tmem119). For the hippocampus, only one main effect of age was observed in adult and 
aged mice fed low and high fiber diets (Il1b, p=0.0325, Tnf, p=>0.05, and Il-6, p>0.05) (Figure 
9A-C). Due to low DNA yield, we were not able to assess Il1b DNA methylation in microglia. 
However, in the hippocampus (Figure 4.9D-E), analysis of Il1b DNA methylation revealed a 
main effect of age in Il1b CpG2 (p=0.001) and an interaction (p=0.0064) in that aged mice had 
less DNA methylation than both adult groups but adult mice with the high fiber diet had 
increased DNA methylation compared to adult mice with the low fiber diet. There were no 
changes in Il1b CpG1. With regards to the periphery, colon, lymph nodes, and liver gene 
expression were analyzed in the same way as Figure 8. The only effect of diet was Ffar2 colon 
gene expression (p=0.0179), in that Ffar2 increased in aged animals with the high fiber 








Figure 4.9. Hippocampal gene expression and DNA methylation at 4 hours after i.p. LPS injections in 
adult and aged mice fed either a low or high fiber diet. Data are presented as means ± SEM (n=7-10) for 
(A) Il1b, (B) Tnf, and (C) Il-6 gene expression. Data are presented as means ± SEM (n=7-10) for DNA 
methylation of the Il1b promoter in hippocampus at (D) CpG1 and (E) CpG2. Treatment means with 






















Table 4.6. Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in microglia 
collected at 4 hours after SAL/LPS i.p. injections in aged mice pre-treated with i.p. SAL/NaB. Data are 
presented as means ± SEM (n=7-10) and p-values for main effects of NaB and LPS as well as NaB x LPS 
interactions are also included. 
 
A. Inflammatory and Regulators of Inflammatory Genes 
 p-values 
Gene Adult LF Adult HF Aged LF Aged HF Age Diet Age x Diet 
Casp1 0.89±0.11 1.10±0.13 0.98±0.11 0.84±0.09 0.415 0.744 0.127 
Cd68 1.40±0.13 1.70±0.14 2.03±0.19 1.68±0.20 0.075 0.882 0.058 
Cx3cr1 0.53±0.06 0.80±0.09 0.59±0.06 0.54±0.06 0.166 0.131 0.025* 
HIF-1a 3.40±0.71 3.07±0.41 3.00±0.932 2.96±0.36 0.697 0.780 0.831 
Ido1 1.95±0.28 1.78±0.28 2.36±0.50 2.37±0.42 0.191 0.839 0.813 
Igf1 0.45±0.17 0.40±0.12 2.08±0.77 1.36±0.75 0.018* 0.468 0.522 
Il-1β 7.17±1.04 8.01±0.80 12.41±1.07 14.55±2.10 <0.0001* 0.252 0.614 
Il-1rn 10.38±1.94 8.31±1.48 15.19±3.22 18.89±3.59 0.005* 0.761 0.280 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Il-10 7.42±1.88 5.46±0.72 9.64±1.93 9.38±1.67 0.070 0.507 0.609 
Il-6 3.00±0.40 3.24±0.40 2.77±0.30 3.60±0.33 0.858 0.150 0.423 
Niarc1 11.79±1.88 15.09±2.05 11.96±0.88 13.03±2.22 0.604 0.232 0.540 
Nlrp3 2.56±0.37 2.87±0.36 2.45±0.27 2.65±0.45 0.649 0.485 0.887 
Pycard 2.14±0.25 2.62±0.34 2.31±0.19 2.26±0.22 0.704 0.401 0.314 
Socs1 1.13±0.05 1.02±0.07 0.97±0.05 0.99±0.08 0.163 0.474 0.280 
Socs3 8.86±0.97 8.37±0.67 11.08±1.11 9.33±1.48 0.153 0.312 0.566 
Stat3 4.08±0.50 4.32±0.53 3.62±0.34 3.06±0.41 0.064 0.722 0.385 
Tlr2 3.03±0.51 2.58±0.32 3.17±0.29 3.44±0.56 0.250 0.832 0.399 
Tlr4 0.72±0.07 1.00±0.14 0.80±0.06 0.77±0.06 0.439 0.171 0.097 
Tlr7 2.35±0.27 3.24±0.50 1.87±0.19 1.67±0.16 0.002* 0.280 0.091 
Tlr8 3.51±0.59 4.56±0.97 6.07±1.21 4.36±0.71 0.208 0.723 0.142 
Tnf 4.77±0.64 6.65±0.79 7.02±0.75 7.66±0.81 0.034* 0.100 0.411 
 
B. Sensome Genes 
     p-values 
Gene Adult LF Adult HF Aged LF Aged HF Age Diet Age x Diet 
Cd53 1.83±0.27 3.19±0.87 0.91±0.17 2.67±0.73 0.297 0.028* 0.778 
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Gpr34 0.23±0.04 0.40±0.08 0.20±0.03 0.21±0.06 0.064 0.119 0.167 
P2ry12 0.45±0.06 0.71±0.12 0.41±0.05 0.33±0.06 0.011* 0.263 0.047* 
P2ry13 1.03±0.09 1.61±0.23 0.97±0.09 0.82±0.07 0.004* 0.136 0.013* 
Siglech 0.71±0.07 1.04±0.15 0.67±0.05 0.59±0.05 0.010* 0.199 0.035* 
Tgfbr1 1.04±0.12 1.80±0.36 1.02±0.14 0.96±0.15 0.054 0.120 0.065 
Tmem119 1.00±0.17 2.36±0.49 1.28±0.25 1.34±0.32 0.271 0.036* 0.056 
Trem2 1.73±0.19 2.66±0.33 2.03±1.34 1.46±0.25 0.123 0.527 0.011* 
 
C. Epigenetic Regulator Genes 
     p-values 
Gene Adult LF Adult HF Aged LF Aged HF Age Diet Age x Diet 
Dnmt3a 0.74±0.08 0.94±0.12 0.93±0.10 0.86±0.09 0.577 0.509 0.185 
Dnmt3b 1.80±0.12 2.40±0.36 1.76±0.14 1.74±0.20 0.142 0.212 0.187 
Gadd45b 3.83±0.62 4.75±0.57 6.27±0.68 7.25±1.03 0.0012* 0.006* 0.033* 
Hdac1 0.90±0.03 0.81±0.04 0.75±0.04 0.78±0.04 0.012* 0.375 0.101 
Gene SAL + SAL ZEB + SAL SAL + LPS ZEB + LPS ZEB LPS ZEB x LPS 
Hdac2 2.15±0.40 2.45±0.33 2.46±0.60 1.75±0.54 0.680 0.678 0.297 
Hdac3 1.33±0.14 1.61±0.23 1.34±0.10 1.16±0.10 0.162 0.776 0.149 
Hdac4 7.70±1.19 8.46±1.38 5.70±0.90 5.22±1.52 0.043* 0.913 0.624 
Hdac5 0.45±0.08 1.33±0.30 0.61±0.12 0.70±0.18 0.236 0.015* 0.045* 
Hdac6 3.44±0.45 3.79±0.80 3.38±0.76 3.33±0.94 0.735 0.841 0.800 
Mecp2 1.42±0.16 1.76±0.20 1.35±0.11 1.22±0.12 0.052 0.498 0.140 
Tet1 0.30±0.09 0.65±0.12 0.34±0.06 0.47±0.12 0.512 0.023* 0.279 
Tet2 2.74±0.37 3.21±0.45 2.24±0.30 2.18±0.38 0.050* 0.589 0.492 
Tet3 5.85±1.77 6.35±2.44 1.20±0.35 5.67±1.95 0.250 0.284 0.390 
 
Table 4.6 (cont.). Expression of (A) inflammatory, (B) sensome, and (C) epigenetic regulator genes in 
microglia collected at 4 hours after SAL/LPS i.p. injections in aged mice pre-treated with i.p. SAL/NaB. 
Data are presented as means ± SEM (n=7-10) and p-values for main effects of NaB and LPS as well as 
NaB x LPS interactions are also included. 
 
4.5 Conclusion  
These studies tested the hypotheses that (1) NaB pharmacologically could be anti-
inflammatory for aged microglia, (2) a high soluble fiber diet has the potential to be anti-
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inflammatory for aged microglia through increases in butyrate and changes in the 
microbiome/periphery, and that (3) a high soluble fiber diet could diminish the aged microglial 
phenotype seen during an immune challenge. 
First, we demonstrated that LPS-induced Il1b gene expression was decreased in microglia 
and hippocampus in NaB-pretreated aged mice. There were similar trending effects in adult 
mice, but effects were much more pronounced in the aged. This may be due to the fact that 
HDAC inhibitor effectiveness on controlling epigenetic regulation in the brain may vary widely 
depending on experience (Sewal et al., 2015). Nonetheless, our results support the fact that 
butyrate can decrease pro-inflammatory cytokine expression in microglia, similar to previous 
findings (Huuskonen et al., 2004; Patnala et al., 2016). Because NaB exerted an anti-
inflammatory effect on microglia in our aged mouse model, we wanted to determine whether an 
increase in butyrate through a high soluble fiber diet has the potential to alter neuroinflammation.  
Before starting the diet study, we performed a microbiome analysis between adult and 
aged mice to determine whether aged mice had an altered microbiome, a finding that has been 
shown previously and reported to be related to increased inflammation seen with aging (Langille 
et al., 2014; Thevaranjan et al., 2017). Of note, there were lower levels of Mucuspirillum spp. 
and Odoribacter spp., and higher levels of in Ruminococcus spp., Coprococcus spp., and 
Rikenellaceae in aged versus adult mice. Increases in Ruminococcus spp has been shown in 
elderly humans that was associated with high frailty scores (van Tongeren, Slaets, Harmsen, & 
Welling, 2005) and increases in Rikenellaceae have been shown in aged mice compared to adult 
mice (Neyrinck et al., 2017). Interestingly, when we performed a microbiome analysis at the end 
of the diet study (4 weeks), high fiber decreased both Ruminococcus spp and Rikenellaceae, 
indicative of a potential beneficial effect. Although we did not find any specific species effects, 
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fermentation of fiber is thought to contribute significantly to butyrate production in the colon and 
is dominated by Ruminococcus bromii (Ze, Duncan, Louis, & Flint, 2012). Surprisingly, we saw 
no differences in the butyryl-CoA:acetate CoA-transferase gene (data not shown), a gene that is 
thought to be a valuable marker for gastrointestinal microbiota function and increased butyrate 
production/butyrate producing bacteria (Hippe et al., 2011). However, SCFA analysis did reveal 
significant increases in butyrate along with acetate and total SCFA production with the high fiber 
diet. This discrepancy in results may be due to the fact that mice were only on low and high fiber 
diets for 4 weeks. A 2 or 3 month diet intervention may be necessary to see more pronounced 
changes.   
Results of the Fluidigm gene expression analysis indicated that a high fiber diet created 
an anti-inflammatory profile in microglia, as many inflammatory genes were decreased by diet or 
in combination with age (Il1b, Il-1rn, Il-6, Nlrp3, Tlr4, Tnf). Novel findings also indicated 
changes in sensome and epigenetic regulator genes, suggesting that high fiber can promote 
changes in a microglial-specific and epigenetic-dependent manner. Since Il1b, Tnf, and Il-6 gene 
expression was strongly decreased by diet, we correlated these genes with corresponding 
concentrations of butyrate in the mice. For Il1b and Tnf (trend for Il-6), higher butyrate 
correlated with lower pro-inflammatory gene expression. The mechanisms behind such an 
association are unclear, but many possible explanations exist, including regulation of FFARs on 
peripheral immune cells signaling to the brain or differential activation of the vagus nerve (Mu, 
Yang, & Zhu, 2016).  
Since DNA methylation has been shown to be affected by butyrate and other dietary 
factors (vel Szic, Declerck, Vidaković, & Vanden Berghe, 2015), Il1b DNA methylation in the 
hippocampus was measured. There were no DNA methylation changes related to diet, but as 
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there were no significant effects of diet in the pro-inflammatory genes measured in the 
hippocampus, this is not surprising. This strengthens the ideas that the anti-inflammatory 
changes seen with diet are microglial-specific. We hypothesize that DNA methylation changes 
would be observed in microglia, but this was not able to be measured due to low DNA yield. It 
will be important to confirm these results in the future, along with histone modifications and 
DNA hydroxymethylation changes that are known to be affected in Il1b (Haseeb, Makki, & 
Haqqi, 2014; W. Schaafsma et al., 2015). Furthermore, it is exciting that newly discovered 
histone modifications such as histone propionylation and butyrylation could have the potential to 
be regulated by dietary fiber (Kebede et al., 2017). 
A surprising finding was that although significant pro-inflammatory gene expression 
changes with diet were observed in microglia, these changes were not mirrored in the colon, 
lymph nodes, or liver. This could be due to length of the diet as mention previously, or effects 
have potentially been masked due to the heterogeneous mix of cells in colon tissue. There were 
however effects of diet in the colon for Tjp2 and trending effects for Tjp1 and Ocln in that high 
fiber diet increased all of the genes, indicating a beneficial change in gut permeability. Higher 
tight junction protein expression would be expected as increases in butyrate have been shown to 
upregulate tight junction proteins (Bordin, Atri, Guillemot, & Citi, 2005). There was also a 
significant decrease in Ffar2, which may be related to decreased neutrophil infiltration (Fournier 
& Parkos, 2012). Scoring of histology sections for inflammatory infiltrate revealed that aged 
mice on a low fiber diet had dramatically increased leukocyte infiltration, and that aged mice on 
the high fiber diet have decreased inflammatory infiltrate, with scoring not significantly different 
from either low fiber or high fiber adult groups. This demonstrates that a low fiber diet creates an 
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increased inflammatory environment that is more pronounced in aged, and that a high fiber diet 
has a potential to decrease these inflammatory changes.  
Our last experiment was designed to determine whether a high fiber diet could diminish 
the exaggerated inflammatory response in aged mice during an immune challenge. We found that 
when both adult and aged mice were fed low and high fiber diets and injected with LPS, there 
were minimal effects of diet on both the brain and the periphery at the peak immune response (4 
hours). However, it is interesting to note that there was an interaction of age x diet in one of the 
CpG sites analyzed for Il1b DNA methylation, in that aged mice had less DNA methylation than 
both adult groups, but adult mice with the high fiber diet had increased DNA methylation 
compared to adult mice with the low fiber diet. This may indicate that DNA methylation is more 
dynamic and responsive to a dietary intervention in adults (Jones, Goodman, & Kobor, 2015), 
but the mechanism of this is unclear. Using a lower dose of LPS or an infection such as influenza 
to more accurately mimic a typical immune response in humans may be necessary to see more 
nuanced changes and understand the epigenetic mechanisms involved in the inflammatory 
response of aged individuals. 
 In conclusion, data thus far supports a role of high fermentable fiber in altering the 
microbiome and potentially immune infiltration/gut permeability, which supports beneficial 
microglial function in aged mice. More work needs to be performed to examine the mode of 
action of butyrate-producing diets in the brain and whether or not these changes relate to the 
beneficial effects seen with NaB. The characteristic that butyrate is synthesized endogenously 
via fermentation of non-digestible fibers by bacteria in the colon makes the prevention or at least 
suppression of neuroinflammatory conditions such as aging possible (Bourassa et al., 2016). 
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High fiber supplementation in the elderly therefore may be a non-invasive strategy to increase 
























CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
The studies in this dissertation sought to examine the role of epigenetic mechanisms in 
microglia during aging. Our findings demonstrated that microglia of aged mice do indeed have 
differential epigenetic regulation, including decreased methylation of the Il1b gene basally or 
following LPS, as well as changes in gene expression of epigenetic regulators (Matt et al., 2016). 
Furthermore, we found that inhibiting DNA methylation increased Il1b gene expression and 
decreased DNA methylation of BV2 and primary microglial cells similar to microglia from aged 
mice.  
Since inhibiting DNA methylation was able to produce a heightened pro-inflammatory 
response in microglia in vitro, we investigated whether inhibiting DNA methylation in the brain 
of adult mice would alter sickness behavior, DNA methylation of the Il1b promoter and 
expression of inflammatory genes in microglia similar to aged mice. Instead, we found that 
inhibiting DNA methylation with a DNMT inhibitor produced anti-inflammatory effects in vivo, 
including decreased sickness behavior when injected with LPS and decreased gene expression of 
inflammatory markers. Interestingly, DNA methylation of Il1b proximal promoter was changed 
by inhibiting DNA methylation alone or in combination with LPS, and these changes persisted 
48 hours after LPS treatment, when gene expression changes were no longer present.  
Lastly, we were interested in examining the effects of butyrate in microglia of aged mice, 
using both injections of butyrate and increases in butyrate through a highly fermentable diet. We 
found that both pre-treatment of NaB and a 4-week feeding of a high fiber diet decreased gene 
expression of inflammatory markers in microglia, and that this was more pronounced in aged 
animals. We also found that epigenetic regulators and the microglial sensome were altered by 
both diet and age. 
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In order to move forward with the findings from this dissertation, it is important to 
discuss the limitations of these studies and suggest several lines of research to pursue. First, the 
focus of epigenetic findings in this dissertation was limited to DNA methylation, so it will be 
important to characterize other epigenetic mechanisms altered in healthy aging microglia. These 
include changes in DNA hydroxymethylation, histone modifications, and microRNAs. As a 
number of epigenetic signatures have been found for age-related diseases in microglia 
(Coppieters et al., 2014; Tang et al., 2014; Thome, Harms, Volpicelli-Daley, & Standaert, 2016; 
Zhu et al., 2017), it would be beneficial to make comparisons. 
In Chapter 3, although we found the DNMT inhibitor to be overall anti-inflammatory 
when we measured sickness behavior and microglial transcriptional activity, we did not look at 
the role of the peripheral immune system in this model. An essential next step would be to 
determine the role of DNMT inhibition in response to peripheral immune stimulation (giving 
mice an i.p. LPS injection instead of an i.c.v. injection).  As the brain and peripheral immune 
system have many routes of communication (Dilger & Johnson, 2008), extending the findings of 
this study could uncover specific pathways involved in regulating DNA methylation in 
microglia. Further, combined treatments of epigenetic drugs such as DNMT inhibitors and 
HDAC inhibitors could elicit even more favorable microglia activity, as in vitro studies from our 
lab suggest (unpublished data). 
In Chapter 4, we found increases in butyrate with a highly fermentable diet along with 
anti-inflammatory effects in microglia. However, we found limited effects in the periphery, and 
specifically we surprisingly found very few changes in butyrate-producing bacteria with our 
microbiome analysis. This suggests that a longer diet (2-3 month) study might be necessary to 
further increase butyrate and uncover additional benefits. It would also be important to take a 
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more mechanistic approach in order to understand how the microbiome is communicating with 
the immune system and specifically microglia in the brain. Utilization of transgenic mice to 
specifically knock out HDACs or FFARs in microglia, gut epithelial cells, or peripheral immune 
cells (Abram, Roberge, Hu, & Lowell, 2014; Feng et al., 2013; Parkhurst et al., 2013; Yona et 
al., 2013), or utilization of germ free mice and then recolonizing with specific butyrate producing 
bacteria to manipulate the microbiome (Donohoe et al., 2011) are invaluable tools necessary to 
better understand our findings.     
Lastly, another limitation is that microglial morphology was not quantified in these 
studies. Altered microglial morphology has been reported extensively in both aged human and 
rodent brains (Davies, Ma, Jegathees, & Goldsbury, 2017; Norden & Godbout, 2013; Streit, 
Sammons, Kuhns, & Sparks, 2004). Therefore, using immunohistochemistry, valuable findings 
could be obtained to understand whether or not our transcriptional changes found with epigenetic 
modifiers correlate with changes in microglial morphology or if colocalization of proteins of 
interest exist. 
Collectively, the aforementioned experiments suggest that epigenetic modifications are 
altered in aged microglia and have the ability to induce different microglial phenotypes. As 
stated at the beginning of this dissertation, it is still not completely understood whether 
inflammatory pathways become more activated with age, or whether the immune system fails to 
mount appropriate inflammatory responses due to age-related deterioration (Lucin & Wyss-
Coray, 2009). The studies presented herein suggest that there could be a combination of both 
scenarios, as heightened inflammation is present in aged animals but the transcripts encoding 
proteins and receptors involved in detecting ligands and microbes (sensome genes) are 
consistently downregulated. Our findings also suggest that using both pharmacological agents 
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and non-pharmacological interventions like a high soluble fiber diet that act as epigenetic 
modifiers may potentially modulate this imbalance in microglial cell function. It will be 
important in the future to better understand these responses to epigenetic modifiers, through diet 
or pharmacological agents, and to create a personalized approach of combination therapy in 
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